Document:

EX-10.12

 Exhibit 10.12 
  

 
 VIA HAND DELIVERY 

March 27, 2013 (as amended April 2, 2013) 
 Adrian
Senderowicz, MD 
 Dear Adrian: 
 In connection
with the termination of your employment with Tokai Pharmaceuticals, Inc. (the “Company”) on March 27, 2013, and pursuant to the terms of your July 19, 2012 Offer Letter with the Company, you are eligible to receive the severance
benefits described in paragraph 2 below if you sign and return this letter agreement to me by April 4, 2013. By signing and returning this letter agreement, you will be entering into a binding agreement with the Company and will be agreeing to
the terms and conditions set forth in the numbered paragraphs below, including the release of claims set forth in paragraph 3. Therefore, you are advised to consult with an attorney before signing this letter agreement and you have been given at
least seven (7) days to do so. 
 If you choose not to sign and return this letter agreement by April 4, 2013, you shall not
receive any severance benefits from the Company. You did, however, receive payment for your final wages and any unused vacation time accrued through the Termination Date (as defined below). You may also, if eligible, elect to continue receiving
group medical insurance pursuant to the “COBRA” law. Please consult the COBRA materials to be provided by the Company under separate cover for details regarding these benefits. In addition, in accordance with your incentive stock option
agreement, you will have 90 days after the Termination Date to exercise your stock option to purchase the 154,776 shares that had vested as of the Termination Date (the “Vested Shares”). All unvested stock rights were cancelled on your
Termination Date. 
 The following numbered paragraphs set forth the terms and conditions that will apply if you timely sign and return this
letter agreement. 
 1. Termination Date—Your effective date of termination from the Company was March 27, 2013 (the
“Termination Date”). As of the Termination Date, all salary payments from the Company ceased and any benefits you had as of the Termination Date under Company-provided benefit plans, programs, or practices terminated, except as required by
federal or state law. 
 2. Description of Severance Benefits—If you timely sign and return this letter agreement and
abide by all of its conditions, the Company will, during the “Severance Period” (as defined below), continue to pay to you as severance pay your base salary rate as of your Termination Date. The Severance Period is the period beginning on
the effective date of this letter agreement (the “Effective Date”) and ending on the earlier of (x) six (6) months following the Effective Date, or (y) the date on which you commence employment with, or commence working as a
consultant or independent contractor for, another employer or entity. You are required to immediately provide the Company with written notice upon your commencement of employment with or provision of services to another person, employer, or entity.
Any severance pay during the Severance Period will be paid in installments in accordance with the Company’s normal payroll practices, but in 

  

 
no event shall payment begin earlier than the date on which you execute this letter agreement. 

3. Release—In consideration of the payment of the severance benefits, which you acknowledge you would not otherwise be
entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their respective past and present
officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the “Released Parties”)
from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations,
liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties, including, but not limited to, any and all claims arising out of or relating to
your employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C.
§ 12101 et seq., the Genetic Information Nondiscrimination Act of 2008. 42 U.S.C. § 2000ff et seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and
Retraining Notification Act (“WARN”), 29 U.S.C. § 2101 et seq., the Rehabilitation Act of 1973, 29 U.S.C. § 701 et seq. Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. §
1681 et seq., and the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1001 et seq., all as amended; all claims arising out of the Massachusetts Fair Employment Practices Act., Mass. Gen. Laws ch. 151B,
§1 et seq., the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, § 148 et seq. (Massachusetts law regarding payment of wages and overtime), the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12,
§§ 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, § 102 and Mass. Gen. Laws ch. 214, § 1C, the Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, § 1 et seq., Mass. Gen. Laws ch. 214,
§ 1B (Massachusetts right of privacy law), the Massachusetts Maternity Leave Act, Mass. Gen. Laws ch. 149, § 105D, and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, § 52D, all as amended; all common law
claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract (including, without limitation, all claims arising out of or related to
your July 19, 2012 Offer Letter); all claims to any non-vested ownership interest in the Company, contractual or otherwise: all state and federal whistleblower claims to the maximum extent permitted by law; and any claim or damage arising out
of your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this
letter agreement (a) waives any right you have to exercise your stock option with respect to the Vested Shares; or (b) prevents you from filing a charge with, cooperating with, or participating in any proceeding before the Equal Employment
Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such claim, charge or proceeding). 

4. Continuing Obligations—You acknowledge and reaffirm your obligation to keep confidential and not to use or disclose any
and all non-public information concerning the Company that you acquired during the course of your employment with the Company, including, but not limited to. any non-public information concerning the Company’s business affairs, business
prospects, and financial condition. You further 

  
 - 2 - 

 
acknowledge and reaffirm your obligations set forth in the Confidentiality, Inventions, Non-Competition and Non-Solicitation Agreement you executed for the benefit of the Company, which remain in
full force and effect. 
 5. Non-Disparagement—You understand and agree that you will not, in public or private, make any
false, disparaging, derogatory or defamatory statements to any person or entity, including, but not limited to, any media outlet, industry group, financial institution or current or former employee, board member, consultant, client or customer of
the Company, regarding the Company or any of the other Released Parties, or regarding the Company’s business affairs, business prospects, or financial condition. 

6. Continued Assistance—You agree that after the Termination Date you will provide all reasonable cooperation to the
Company, including but not limited to, assisting the Company in transitioning your job duties and performing any other tasks as reasonably requested by the Company. 

7. Cooperation—To the extent permitted by law, you agree to cooperate fully with the Company in the defense or prosecution
of any claims or actions which already have been brought, are currently pending, or which may be brought in the future against or on behalf of the Company, whether before a state or federal court, any state or federal government agency, or a
mediator or arbitrator. Your full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel to prepare its claims or defenses, to prepare for trial or discovery or an
administrative hearing or a mediation or arbitration and to act as a witness when requested by the Company at reasonable times designated by the Company. You agree that you will notify the Company promptly in the event that you are served with a
subpoena or in the event that you are asked to provide a third party with information concerning any actual or potential complaint or claim against the Company. 

8. Return of Company Property—You confirm that you have returned to the Company all keys, files, records (and copies
thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones, pagers, etc.), Company identification, and any other Company-owned property in your possession or control and
have left intact all electronic Company documents, including but not limited to those that you developed or helped to develop during your employment. You further confirm that you have cancelled all accounts for your benefit, if any, in the
Company’s name, including but not limited to, credit cards, telephone charge cards, cellular phone and/or pager accounts, and computer accounts. 

9. Business Expenses and Final Compensation—You acknowledge that you have been reimbursed by the Company for all relocation
expenses and business expenses you incurred in conjunction with the performance of your employment and submitted to the Company as of the Termination Date. The Company will also reimburse you, in accordance with the terms and conditions of its
expense reimbursement policy and practice, for all business expenses you incurred during and in conjunction with your employment but did not submit as of the Termination Date, provided you submit such expenses by May 3, 2013. In addition, the
Company will reimburse you for any relocation expenses you incurred as of the Termination Date but did not submit for reimbursement by such date, up to a maximum of $34,531, provided you submit such expenses by May 3, 2013. You acknowledge that
you have received payment in full for all services rendered in conjunction with your employment by the Company, including payment for all wages (including overtime), bonuses, and accrued, unused vacation time, and that no other compensation is owed
to you except as provided herein. 

  
 - 3 - 

 10. Amendment and Waiver—This letter agreement shall be binding upon the
parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto. This letter agreement is binding upon and shall inure to the benefit
of the parties and their respective agents, assigns, heirs, executors, successors and administrators. No delay or omission by the Company in exercising any right under this letter agreement shall operate as a waiver of that or any other right. A
waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion. 

11. Validity—Should any provision of this letter agreement be declared or be determined by any court of competent
jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement. 

12. Confidentiality—To the extent permitted by law, you understand and agree that as a condition for payment to you of the
severance benefits herein described, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting in this letter agreement, shall be maintained as confidential by you and your agents and
representatives and shall not be disclosed except as otherwise agreed to in writing by the Company. 
 13. Nature of
Agreement—You understand and agree that this letter agreement is a severance agreement and does not constitute an admission of liability or wrongdoing on the part of the Company. 

14. Acknowledgments and Voluntary Assent—You acknowledge that you have been given at least seven (7) days to consider
this letter agreement, and that the Company is hereby advising you to consult with an attorney of your own choosing prior to signing this letter agreement. You affirm that no other promises or agreements of any kind have been made to or with you by
any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand the meaning and intent of this letter agreement. You further state and represent that you have carefully read this letter agreement, understand
the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign your name of your own free act. 
 15.
Applicable Law—This letter agreement shall be interpreted and construed by the laws of the Commonwealth of Massachusetts, without regard to conflict of laws provisions. You hereby irrevocably submit to and acknowledge and
recognize the jurisdiction of the courts of the Commonwealth of Massachusetts, or if appropriate, a federal court located in the Commonwealth of Massachusetts (which courts, for purposes of this letter agreement, are the only courts of competent
jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof. 

16. Entire Agreement—This letter agreement contains and constitutes the entire understanding and agreement between the
parties hereto with respect to your severance benefits and the settlement of claims against the Company and cancels all previous oral and written negotiations, agreements, and commitments in connection therewith. Nothing in this paragraph, however,
shall modify, cancel or supersede your obligations set forth in paragraph 4 above. For the avoidance of doubt, your July 19, 2012 Offer Letter is terminated as of March 27, 2013 and is of no further force or effect. 

  
 - 4 - 

 17. Tax Acknowledgement—In connection with the severance benefits provided to
you pursuant to this letter agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall be responsible for all applicable taxes with respect to such severance benefits under
applicable law. You acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of any of the severance benefits set forth in paragraph 2 of this letter agreement. 

If you have any questions about the matters covered in this letter agreement, please call me. 

 

			
	Very truly yours,
		
	By:	 	/s/ Seth L. Harrison
		 	 Seth L. Harrison, MD
 Chairman of the
Board

 I hereby agree to the terms and conditions set forth above. I intend that this letter agreement become a
binding agreement between me and the Company. 
  

					
	 /s/ Adrian Senderowicz

Adrian Senderowicz, MD
	  		  	 4/3/2013

Date

 To be returned by April 4, 2013. 

  
 - 5 -EX-10.14

 Exhibit 10.14 

Confidential Materials omitted and filed separately with the 

Securities and Exchange Commission. Double asterisks denote omissions. 

 
 

 
  
  

MASTER LICENSE AGREEMENT 

BETWEEN 
 UNIVERSITY OF
MARYLAND, BALTIMORE 
 AND 

TOKAI PHARMACEUTICALS, INC. 
  

 
 UMB Docket Nos.: 

 AB-93-031 

AB-96-031 
 AB-98-014

 VN-2002-019 

 MASTER LICENSE AGREEMENT TABLE OF CONTENTS 

 

					
	 	  	Page	 
	 ARTICLE 1 BACKGROUND
	  	 	1	  
		
	 ARTICLE 2 DEFINITIONS
	  	 	1	  
		
	 ARTICLE 3 GRANT OF LICENSE
	  	 	7	  
		
	 ARTICLE 4 DILIGENCE REQUIREMENTS
	  	 	14	  
		
	 ARTICLE 5 CONSIDERATION
	  	 	14	  
		
	 ARTICLE 6 PATENT PROSECUTION AND PUBLICATIONS
	  	 	18	  
		
	 ARTICLE 7 CONFIDENTIALITY
	  	 	20	  
		
	 ARTICLE 8 REPORTS, PAYMENTS, AND ACCOUNTING
	  	 	22	  
		
	 ARTICLE 9 INFRINGEMENT
	  	 	23	  
		
	 ARTICLE 10 TERM AND TERMINATION
	  	 	25	  
		
	 ARTICLE 11 MISCELLANEOUS AGREEMENTS
	  	 	27	  
		
	 ARTICLE 12 REPRESENTATIONS AND WARRANTIES
	  	 	28	  
		
	 ARTICLE 13 CLAIMS, INDEMNIFICATION, AND INSURANCE
	  	 	30	  
		
	 ARTICLE 14 DISPUTE RESOLUTION
	  	 	31	  
		
	 ARTICLE 15 NOTICES AND INVOICES
	  	 	32	  
		
	 ARTICLE 16 ASSIGNMENT
	  	 	33	  
		
	 ARTICLE 17 MISCELLANEOUS
	  	 	34	  

 Schedules 
  

	A	PATENT RIGHTS 

  

	B	DUE DILIGENCE MILESTONES 

 MASTER LICENSE AGREEMENT 

This Master License Agreement (“Agreement”) is effective as of the date of the last signature on the Signature Page
(“Effective Date”), and is made by and between the UNIVERSITY OF MARYLAND, BALTIMORE (“UMB”), a constituent institution of the University System of Maryland (“USM”) (which is a public corporation
and an instrumentality of the State of Maryland), having an address at 515 West Lombard Street, Fourth Floor, Baltimore, Maryland 21201, and TOKAI PHARMACEUTICALS, INC., a Delaware corporation (“Company”), with its principal place
of business at 1 Broadway, 14th Floor, Cambridge, MA 02142. 
 ARTICLE 1. BACKGROUND 

1.1 Valuable inventions (“Inventions”) generally known as “Androgen Synthesis Inhibitors,” have been made by
Angela Brodie, Ph.D., Jisong Li, Ph.D., Vincent Njar, Ph.D., and Yangzhi Ling (“Inventors”). 
 1.2 Subject to
certain rights retained by the U.S. Government in inventions resulting from federally supported work, under USM policy USM owns an interest in and to the Inventions and Patent Rights (as defined below) relating to the Inventions, which has been
confirmed by the execution of assignments to UMB from the Inventors. 
 1.3 As a public research and education institution, UMB is
interested in licensing the Patent Rights to Company, which desires to license the Patent Rights on the terms and conditions set forth in this Agreement. 

ARTICLE 2. DEFINITIONS 
 In this
Agreement, the following terms have the meanings set forth in this Article. 
 “BLA”: A Biologies License Application submitted to FDA.

 “Business Day”: a day other than a Saturday, Sunday, federal holiday, or holiday observed by UMB. 

“Claim”: Any claim of an issued and unexpired patent or claim of a pending patent application contained in the Patent Rights which has
not: lapsed; been irrevocably withdrawn or abandoned; been held permanently revoked, unenforceable or invalid by a final decision of a court or other governmental agency of competent jurisdiction; been held unappealable or unappealed within the time
allowed for appeal; or been admitted by UMB to be invalid or unenforceable. 
 “Clinical Trial:” A human clinical trial of a
Licensed Product that satisfies the requirements of 21 C.F.R. §312.21, or its foreign equivalent. A Clinical Trial shall be considered to have commenced when the Licensed Product has been administered to the first subject in the study. A
Clinical Trial shall be considered to have been completed upon the earlier of: (a) the submission of all case report forms for qualified study subjects by the principal 

  
 1 

 
investigators) to Company or its designee in accordance with the protocol and substantially all analysis thereof has been completed, or (b) when the trial is reported as closed to the
Institutional Review Board(s) of record. 
 “Combination Product”: A Licensed Product that contains at least one (1) Covered
Component and at least one (1) Non-Covered Component. 
 “Commercially Reasonable Efforts”: As defined in Section
4.2. 
 “Company”: Shall be construed to mean “Tokai Pharmaceuticals, Inc. and/or any Company Affiliate, as the case
may be,” unless the context clearly indicates otherwise. 
 “Company Affiliate”: Any Person which controls, is
controlled by, or is under common control with Company. For purposes of this definition, a Person shall be regarded as in control of another Person if it directly or indirectly owns or controls more than fifty percent (50%) of the voting stock
or other ownership interest of the other Person, or if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the Person or the power to elect or appoint more than fifty percent
(50%) of the members of the governing body of the Person. 
 “Company Confidential Information”: Confidential
Information which (a) is made or owned by one or more Company Personnel or Sublicensee Personnel, or owned by Company or Sublicensee(s); and (b) is actually disclosed prior to the Effective Date or during the Term to TEC-COM or the
Inventors by Company. 
 “Company Improvement”: Any Improvement which: (a) was invented solely by one or more Company
Personnel; or (b) otherwise is owned by Company. 
 “Company Personnel”: (a) Officers, directors, employees, and
agents of Company, and (b) members of Company’s Scientific Advisory Board. 
 “Confidential Information”:
Information (including without limitation documents, notes, drawings, models, designs, data, memoranda, tapes, records, formulae and algorithms, in hard copy form or in electronic form) which has not been made public and which is disclosed by a
Party (the “Disclosing Party”) to the other Party (the “Receiving Party”) in connection with this Agreement, including without limitation information that (a) is related to and results from or arises out of use
of the Inventions, the Improvements, or the Patent Rights, or (b) is reasonably necessary for the practice of the Patent Rights or for the development or commercialization of Licensed Products. 

“Covered Component”: A component of a Combination Product the manufacture, use, or sale of which is covered by a Claim of the Patent
Rights. 
 “Combination Product Net Revenues”: As defined in Section 5.5.2. 

“Effective Date”: The date of the last signature on the Signature Page. 

  
 2 

 “Eligible Sublicensee”: A Sublicensee that: (a) is not in default of its material
obligations under its Sublicense or under any agreement with UMB, USM, or the State of Maryland, and is current on all of its material financial obligations to UMB, USM, or the State of Maryland (including without limitation taxes); (b) is not
an adverse party in any litigation, arbitration, administrative or other similar proceeding with UMB or USM; (c) has not made a general assignment for the benefit of creditors of all or substantially all of its assets; (d) has not
commenced a case under or otherwise sought relief from its obligations under any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution, or liquidation law, statute, or proceeding; (e) has not by any act indicated its consent
to, approval of, or acquiescence in any proceeding or the appointment of a receiver of or trustee for it or a substantial part of its property, or suffered any such receivership or trusteeship to continue undismissed for a period of sixty
(60) days; and (f) is not a debtor in any case under any chapter of the U.S. Bankruptcy Code. 
 “European States”:
Member states of the European Patent Convention (EPC) regional patent system and designated as “EP” in the request of an international patent application filed under the Patent Cooperation Treaty (PCT). 

“Fair Market Value”: For purposes of determining the Fair Market Value of securities hereunder, the following rules shall apply:

  

	 	(a)	If at the time of such issuance the issuing corporation does not have a class of securities registered under the Securities Exchange Act of 1934, as amended (“Exchange Act”), Fair Market Value shall mean the
price per share as determined in good faith by the Board of Directors of the issuing corporation with reference, in the case of any preferred stock, to any recent or then contemplated financing by venture capital or similar investors; and

  

	 	(b)	If at the time of such issuance the issuing corporation has a class of securities registered under the Exchange Act, then (i) if the securities so issued are of the same class as securities of the issuing
corporation then traded on a national securities exchange, in over-the-counter trading, or similar trading system, then Fair Market Value shall be the average trading price over the twenty (20) day period preceding the date of issuance, and
(ii) if the securities are not of the same class as securities of the issuing corporation then so publicly traded, then the Fair Market Value shall be the amount determined in good faith by the Board of Directors of the issuing corporation.

  

	 	(c)	Notwithstanding the foregoing, UMB shall have the right in good faith to dispute any valuation determined by the Board of Directors of the issuing corporation. In that event, any dispute regarding Fair Market Value of
the securities shall be resolved in accordance with Section 14.3. 

 “FDA”: The U.S. Food and Drug
Administration, or any successor agency thereto. 
 “Federal Patent Policy”: As defined in Section 3.5.1. 

  
 3 

 “First Commercial Sale”: The initial Sale of a Licensed Product to a Third Party end
user. 
 “Improvement”: An invention or discovery which: (a) is directly related to the Patent Rights, but is not
included within the definition of Patent Rights; (b) is or may be patentable or otherwise protected or protectable under law; and (c) either (i) cannot be practiced without infringing one or more Claims of the Patent Rights, or
(ii) would itself be infringed by the practicing of the Patent Rights. 
 “IND”: An Investigational New Drug Application
submitted to FDA under Section 505 of the Federal Food, Drug, and Cosmetic Act, which satisfies the requirements of 21 C.F.R. §312. 

“Infringement”: As defined in Section 9.1. 

“Inventions”: As defined in Section 1.1. 

“Inventors”: As defined in Section 1.1. 

“Joint Improvement”: Any Improvement which was invented by one or more Company Personnel and by one or more UMB Personnel. 

“Licensed Field”: The use of Patent Rights in the prevention, diagnosis, treatment or control of any human or animal disease,
disorder, or condition. 
 “Licensed Improvement”: As defined in Section 3.6.5. 

“Licensed Product”: Any product (including without limitation any Combination Product) whose manufacture, use, Sale or import would
infringe the Patent Rights, or any process whose practice would infringe the Patent Rights. 
 “Licensed Territory”:
Worldwide. 
 “NDA”: A New Drug Application submitted to the FDA to market a new drug under Section 505 of the Federal
Food, Drug, and Cosmetic Act, which satisfies the requirements of 21 C.F.R. §313. 
 “Net Revenues”: The gross amounts
invoiced to any Third Party by Company or Sublicensees for Sales of Licensed Products, less the following: 
  

	 	(a)	Trade, quantity and cash discounts, chargebacks, rebates, credits and allowances actually allowed and taken; 

  

	 	(b)	Sales or use taxes, excise taxes, surcharges and customs duties and other governmental charges included in the invoiced amount; 

  

	 	(c)	Distribution fees and sales agent fees or commissions; 

  
 4 

	 	(d)	Amounts invoiced to the customer for outbound transportation, shipping, handling, and insurance; and 

  

	 	(e)	Amounts actually allowed or credited on returns or rejections of Licensed Products, retroactive price reductions or billing errors. 

Combination Product Net Revenues shall be determined in accordance with Section 5.5.2. “Net Revenues” shall also include
any recovery of compensatory or actual damages in an Infringement action, as set forth in Section 9.3.2. “Net Revenues” shall not include (1) any amounts which are within the definition of “Sublicense Income,” or
(2) any amounts in connection with Sales of Licensed Products at or below cost for purposes of clinical trials. 
 “Non-Commercial
Organization”: A government agency; a university or other institution of higher education; an organization of the type described in Section 501(c)(3) of the Internal Revenue Code, and exempt from taxation under Section 501(a) of
the Internal Revenue Code); a nonprofit scientific or educational organization qualified under a state nonprofit organization statute; or any foreign equivalent of any of the foregoing. 

“Non-Commercial Uses”: Research, scholarly use, teaching, education, and other similar uses. 

“Non-Covered Component”: A component of a Combination Product that is an active ingredient or other functional component or product
(including without limitation a delivery or similar device but excluding non-active ingredients or non-proprietary excipients, buffers or similar substances that are formulated with drug products), the manufacture, use, or sale of which is not
covered by a Claim of the Patent Rights. 
 “Option”: As defined in Section 3.6.4. 

“Option Term”: As defined in Section 3.6.5. 

“Optioned Improvement”: As defined in Section 3.6.3. 

“Party”: UMB or Company; “Parties” means collectively UMB and Company. 

“Patent Expenses”: All fees, charges, expenses, and costs incurred before and after the Effective Date in connection with the
preparation, filing, prosecution, issuance, reissuance, reexamination, interference, and/or maintenance of patents or applications for patent or equivalent protection for the Patent Rights, including without limitation all fees and charges of
outside patent counsel. 
 “Patent Rights”: U.S. and foreign patent applications and patents listed in Schedule A, as it may
be amended from time to time by mutual agreement of the Parties or to add Licensed Improvements pursuant to Section 3.6, together with any substitution, divisional, continuation, and continuation-in-part (to the extent a
continuation-in-part contains one or more Claims directed to any of the foregoing); any Letters Patent therefor; any reissue, 

  
 5 

 
renewal, confirmation, revalidation, addition, reexamination, or extension therefrom; and all foreign counterparts or equivalents of any of the foregoing. 

“Person”: A natural person, trustee, corporation, business trust, partnership, limited partnership, limited liability company,
governmental authority, or any other form of legal entity. 
 “Personnel”: Officers, directors, employees, and agents.

 “Phase 1 Clinical Trial”: A Clinical Trial that is intended to initially evaluate the safety and/or pharmacological effect in
subjects, or that would otherwise satisfy the requirements of 21 C.F.R. §312.21(a). 
 “Phase 2 Clinical Trial”: A
Clinical Trial for which a primary endpoint is a preliminary determination of efficacy and/or dose ranges in patients with the disease target being studied, or that would otherwise satisfy the requirements of 21 C.F.R. §312.21(b). 

“Phase 3 Clinical Trial”: A Clinical Trial that is performed after preliminary evidence suggesting effectiveness of the drug has been
obtained and that is intended to gather confirmatory data supporting effectiveness and safety, to provide an adequate basis for physician labeling, or that would otherwise satisfy the requirements of 21 C.F.R. §312.21(c). 

“Post-Termination Approved Sublicense”: A Sublicense that is approved by UMB pursuant to Section 3.3.5. 

“Pre-Approved Sublicense”: A Sublicense that is approved by UMB pursuant to Section 3.3.3. 

“Qualified Sublicense”: As defined in Section 3.3.4. 

“Sales,” “Sell,” “Resell,” or any correlative term: The sale, lease, transfer, or other disposition
of a Licensed Product by Company or Sublicensees in return for any type of consideration. 
 “Sublicense”: Any agreement
pursuant to which all or some of the Patent Rights are licensed, conveyed, assigned, granted rights to, or otherwise transferred. 

“Sublicensee”: A Person (other than a Company Affiliate) to which Company or a Company Affiliate licenses, conveys, assigns, grants
rights to, or otherwise transfers all or some of the Patent Rights. 
 “Sublicense Income”: Consideration in the form of
cash, cash equivalents, or securities received by Company in consideration for the grant to any Sublicensee of a Sublicense of some or all of the Patent Rights, including without limitation up-front fees, license signing fees, license maintenance
fees, milestone payments, success fees, amounts paid for equity of Company by a Sublicensee in excess of its Fair Market Value, and any other consideration paid by or on behalf of the Sublicensee. “Sublicense Income” shall not include
(a) any running royalties based on Sales of Licensed Product by any Sublicensee,  

  
 6 

 
and (b) any payment or consideration received by Company in consideration for anything other than a Sublicense of some or all of the Patent Rights, including without limitation consideration
for any investment in or extension of credit to Company, reimbursement for research rendered by Company or any payments earmarked for research to be performed, or consideration for a license granted under technology other than the Patent Rights.

 “TEC-COM”: The Technology Commercialization Group in UMB’s Office of Research and Development, and any successor to its
responsibilities. 
 “Term”: As defined in Section 10.1. 

“Third Party”: Any Person other than UMB, UMB Personnel, UMB Related Organizations, Company, Company Affiliates or Company
Personnel. 
 “UMB Related Organizations”: University of Maryland Medical System Corporation, faculty practice organizations
of UMB, the Baltimore Veterans Administration Medical Center, USM, and any constituent institutions of the University System of Maryland. 

“UMB Confidential Information”: Confidential Information which either: (1) TEC-COM receives prior to the Effective Date or during
the Term from UMB Personnel; or (2) is actually disclosed prior to the Effective Date or during the Term to Company by TEC-COM or UMB Personnel. 

“UMB Improvement”: An Improvement which: (a) was invented solely by one or more UMB Personnel; or (b) otherwise is owned by
UMB or a UMB Related Organization. 
 “UMB Personnel”: Inventors while they are employed by UMB; and UMB employees, faculty
members, students, trainees, and other individuals working under the supervision or direction of Inventors and using UMB resources and who are subject to the USM IP Policy. 

“USM IP Policy”: The University System of Maryland Policy on Intellectual Property, effective July 1, 2002, as amended, or, as
applicable, the predecessor Policy on Patents, effective May 31, 1990, as amended, and any successor policy adopted by USM regarding intellectual property and applicable to the Patent Rights. 

ARTICLE 3. GRANT OF LICENSE 
 3.1
License. UMB hereby grants to Company, and Company hereby accepts, an exclusive license under the Patent Rights to make, have made, use, Sell, offer to Sell, and import the Licensed Products and otherwise practice the Patent Rights in any
manner, but only during the Term, within the Licensed Field, and in the Licensed Territory. However, the license is subject to: (a) rights of the U.S. under grants to UMB and Federal Patent Policy, and (b) the terms and conditions of this
Agreement, including without limitation Section 3.2. 

  
 7 

 3.2 UMB’s Reservation of Rights. Notwithstanding anything contained herein to the
contrary, UMB specifically reserves for itself and UMB Related Organizations the following rights: 
 3.2.1 To practice under
the Patent Rights and to make and use the Licensed Products on a royalty-free basis solely for Non-Commercial Uses; 
 3.2.2
To license, without the right to Sublicense, Non-Commercial Organizations to practice under the Patent Rights and make and use the Licensed Products on a royalty-free basis solely for their internal Non-Commercial Uses; 

3.2.3 To provide UMB Confidential Information and material covered by the Patent Rights (excluding Company Confidential
Information) to Non-Commercial Organizations, solely for their internal Non-Commercial Uses, if the Non-Commercial Organization agrees in writing in advance not to transfer such material to any other Person; 

3.2.4 To disseminate and publish scientific findings from research related to Patent Rights and/or the Licensed Products, and
to permit UMB Personnel to do the same, subject to Section 6.4 (Publication) and Article 7 (Confidentiality); and 

3.2.5 To license the Patent Rights to Third Parties for applications outside the Licensed Field and/or Licensed Territory. 

Nothing in this Section 3.2 shall imply any obligation on Company or any Sublicensee to supply any Licensed Product, any material
covered by the Patent Rights, or any other technology or any intellectual property rights to UMB or any Non-Commercial Organization. 
  

	3.3	Sublicenses. 

 3.3.1 Authority to Grant. Company may grant
Sublicenses to one or more Sublicensees without consent of UMB, provided that there is no uncured default or material breach of this Agreement by Company at the time of the grant. Company shall provide to UMB a true and complete copy of each
fully-signed Sublicense and amendments thereto, including all exhibits, attachments and related documents reasonably promptly after executing the same. 

3.3.2 Requirements of Sublicenses. 

(a) Any Sublicense shall be consistent with and subject to the relevant terms and conditions of this Agreement. Any Sublicense
shall require that any further Sublicense from a Sublicensee must satisfy the requirements of this Section. 
 (b) Any
Sublicense shall expressly include provisions for the benefit of UMB substantially similar to this Section 3.3 (Sublicenses), Section 5.5 (Running Royalties on Sales of Licensed Products and Combination Products),
Section 5.6 (Sublicense Income), Article 7 (Confidentiality), Article 8 (Reports, Payments, and Accounting), Section 11.4 (Patent Marking), Section 12.2 (Disclaimer of Warranties by UMB), and
Article 13 (Claims, Indemnification, and Insurance). 

  
 8 

 (c) Any Sublicense shall also require that any dispute between Sublicensee and
UMB which may arise upon termination of this Agreement shall be subject to dispute resolution on the terms and conditions set forth in Article 14 (Dispute Resolution) of this Agreement. 

3.3.3 Pre-Approved Sublicenses. 

(a) Company may, at its option, seek UMB’s prior approval of a proposed Sublicense. In that event, prior to execution,
Company shall notify UMB of the identity of the proposed Sublicensee and shall provide to UMB a true and complete copy of the proposed Sublicense in substantially final form. UMB shall have [**] days after receipt to notify Company in writing of its
determination as to whether the Sublicense and Sublicensee are approved and the reasons for its determination. Any Sublicense that is approved by UMB pursuant to this Section shall be a “Pre-Approved Sublicense.” 

(b) UMB shall not unreasonably withhold its approval of a Sublicense and Sublicensee if: (i) the Sublicense complies with
Section 3.3.2; (ii) the proposed Sublicensee is an Eligible Sublicensee at that time; (iii) the Sublicensee has sufficient financial capacity and resources to commercialize the Licensed Products within the scope of the
Sublicense and to fulfill its financial obligations under the Sublicense; (iv) the Sublicensee agrees to make commercially reasonable payments (such as royalties, milestone payments or other fees) under the Sublicense in light of the then
current commercial and regulatory circumstances for the Licensed Products; and (v) the Sublicensee is able to fulfill the diligence obligations required by this Agreement (as they may reasonably be adjusted in light of the then current
commercial and regulatory circumstances for the Licensed Products). 
 (c) In the event of termination of this Agreement,
upon written request of a Sublicensee within [**] days following the effective date of termination, any Patent Rights sublicensed by Company under a Pre-Approved Sublicense shall become directly licensed from UMB to the Sublicensee if as of the
effective date of direct license the Sublicensee is an Eligible Sublicensee. In that event, the Sublicensee shall comply with Section 3.3.6. 

3.3.4 Qualified Sublicenses. 

(a) In the event of termination of this Agreement, upon written request of a Sublicensee within [**] days following the
effective date of termination, any Patent Rights sublicensed by Company under a Qualified Sublicense shall become directly licensed from UMB to the Sublicensee if as of the date of the written request the Sublicensee is an Eligible Sublicensee. In
that event, the Sublicensee shall comply with Section 3.3.6. 
 (b) “Qualified Sublicense” means
a Sublicense that: (i) complies with Section 3.3.2; (ii) contains provisions that require payment by the Sublicensee to Company of amounts that, taken as a whole, are equal to or greater than the amounts payable by Company to
UMB under Section 5.2 (License Maintenance Fees), Section 5.3 (Milestone Payments), Section 5.4 (Minimum Annual Royalty), Section 5.5 (Running Royalties on Sales of Licensed Products and Combination
Products), and Section 5.6 (Sublicense Income); (iii) requires the 

  
 9 

 
Sublicensee to use Commercially Reasonable Efforts to commercialize one or more Licensed Products; and (iv) requires the Sublicensee to achieve the due diligence milestones set forth on
Schedule B (subject to reasonable adjustment based on the field of use and territory of the Sublicense). 
 3.3.5
Post-Termination Approved Sublicenses. 
 (a) In the event of termination of this Agreement, any Sublicensee of Patent
Rights under a Sublicense from Company that is not a Pre-Approved Sublicense or a Qualified Sublicense may request in writing within [**] days following the effective date of termination that UMB directly license those Patent Rights to the
Sublicensee. Not later than [**] days following the request, UMB shall provide written notice to Company and the Sublicensee of its determination as to whether that direct license and Sublicensee are approved and the reasons for its determination.
Any direct license that is approved by UMB pursuant to this Section shall be a “Post-Termination Approved Sublicense.” 

(b) UMB shall not unreasonably withhold approval of that request, if: (i) the Sublicense complies with
Section 3.3.2; (ii) as of the date of the written request the Sublicensee is an Eligible Sublicensee; (iii) the Sublicensee has sufficient financial capacity and resources to commercialize the Licensed Products within the scope
of the Sublicense and to fulfill its financial obligations under the Sublicense; (iv) the Sublicensee agrees to make commercially reasonable payments (such as royalties, milestone payments or other fees) under the Sublicense in light of the
then current commercial and regulatory circumstances for the Licensed Products; and (v) the Sublicensee is able to fulfill the diligence obligations required by this Agreement (as they may reasonably be adjusted in light of the then current
commercial and regulatory circumstances for the Licensed Products). 
 (c) The Sublicensee under a Post-Termination Approved
Sublicense shall comply with Section 3.3.6. 
 3.3.6 Confirmation of the Direct License; Insurance. 

(a) With respect to a Pre-Approved Sublicense, Qualified Sublicense, or Post-Termination Approved Sublicense that is to
survive, the Sublicensee shall promptly confirm in writing that: 
 (i) The Patent Rights are directly licensed to the
Sublicensee by UMB with the same exclusivity, field of use, and territory as contained in the Sublicense; 
 (ii) UMB shall
not have any obligations broader in scope than it has under this Agreement or any obligations of Company to the Sublicensee which are inconsistent with the Federal Patent Policy, other law, or a written USM or UMB policy; 

(iii) The Sublicensee agrees to deliver to UMB all reports that would have been due to Company under its Sublicense after the
date of termination of this Agreement, and to pay to UMB all payments accruing and due after the termination of this Agreement that would have been payable to Company under its Sublicense; 

  
 10 

 (iv) The Sublicensee agrees to achieve the diligence obligations required by the
Sublicense; 
 (v) The Sublicensee agrees to be bound by terms substantially similar to those required by
Section 3.3.2(b), Section 6.1, and Section 6.2, and to the reimbursement of Patent Expenses (which reimbursement will be on a pro rata basis, if more than one Sublicensee receives a direct license following
termination of this Agreement); and 
 (vi) The Sublicensee agrees that any provision of its Sublicense which is
inconsistent with this Agreement shall not be effective as to the relationship between UMB and the Sublicense. 
 (b) With
respect to a Pre-Approved Sublicense, Qualified Sublicense, or Post-Termination Approved Sublicense that is to survive, the Sublicensee shall promptly deliver to UMB a certificate evidencing the insurance coverage required by this Agreement. The
certificate shall evidence that UMB has been listed as an additional insured, and that the insurance was effective no later than the effective date of the termination. 

3.3.7 Non-Survival of Other Sublicenses. In the event of termination of this Agreement, no Patent Rights sublicensed by
Company shall become directly licensed from UMB other than as specifically set forth in this Section. 
 3.3.8 Third Party
Beneficiaries. Each Sublicensee of a Pre-Approved Sublicense, a Qualified Sublicense, or a Post-Termination Approved Sublicense is an intended third party beneficiary of this Section, and the terms of this Section are enforceable by those
Sublicensees against UMB. 
 3.4 No Implied Rights. This Agreement confers no license or rights by implication, estoppel, or
otherwise in any technology, except as explicitly set forth in this Agreement. 
 3.5 Government Rights and Regulations. 

3.5.1 To the extent that any Invention has been funded in whole or in part by the U.S. Government, the U.S. Government retains
certain rights in the Invention under Federal law and applicable regulations, including without limitation 35 U.S.C. §200-212 (the “Federal Patent Policy”). This Agreement is subject in
all respects to the Federal Patent Policy. 
 3.5.2 As a condition of the license granted hereby, Company acknowledges and
agrees to comply with all aspects of the Federal Patent Policy applicable to the Patent Rights, including without limitation the obligation as set forth in the Federal Patent Policy that Licensed Products used or sold in the U.S. be manufactured
substantially in the U.S (unless such obligation is waived in accordance with the Federal Patent Policy). Nothing contained in this Agreement shall obligate UMB to take any action that would conflict in any respect with its past, current or future
obligations to the U.S. Government under the Federal Patent Policy. 
 3.5.3 Solely to the extent set forth in the Federal
Patent Policy, the U.S. Government retains the right in certain circumstances to require UMB to grant to a responsible 

  
 11 

 
applicant a nonexclusive, partially exclusive, or exclusive license to use the Inventions in the applicant’s field of use on terms that are reasonable under the circumstances; or, if UMB
fails to do so, to grant a license itself. 
 3.5.4 The use and disclosure of technical Confidential Information acquired
pursuant to this Agreement and the exercise of Patent Rights granted by this Agreement are subject to the export, assets, and financial control regulations of the U.S., including without limitation restrictions under regulations of the U.S. that may
be applicable to direct or indirect reexportation of technical Confidential Information or of equipment, products, or services directly produced by use of technical Confidential Information. Company is responsible for complying with these
regulations. 
 3.6 Improvements. 

3.6.1 UMB Improvements shall be owned by UMB. Joint Improvements shall be owned jointly by Company and UMB. Company
Improvements shall be owned by Company. 
 3.6.2 UMB shall report promptly to Company in writing each UMB Improvement and/or
Joint Improvement made by UMB during the Term which is disclosed to TEC-COM, and whether that UMB Improvement and/or Joint Improvement is subject to rights of a Third Party which sponsors research at UMB as a result of which the Improvement was
discovered or invented. Company shall report promptly to UMB in writing each Joint Improvement made by Company during the Term. These reports shall be in sufficient detail to determine inventorship and to file and prosecute patent applications for
Improvements. These reports shall be subject to Article 7 (Confidentiality). 
 3.6.3 Company and UMB shall discuss
whether a patent application or applications pertaining to each UMB Improvement and/or Joint Improvement should be filed. If Company notifies UMB in writing that patent application(s) should be filed with respect to any UMB Improvement and/or Joint
Improvement (each, an “Optioned Improvement”), then UMB shall be responsible for preparing and filing such patent applications in accordance with Sections 6.1 and 6.2 hereof and Company shall be responsible for the
reasonable Patent Expenses incurred by UMB for such filings in accordance with Section 3.6.8. If Company notifies UMB in writing that it is not interested in having patent application(s) filed with respect to a particular UMB Improvement
and/or Joint Improvement, or if Company fails to notify UMB of its interest within [**] days from the date on which the Improvement was disclosed by UMB, then Company shall not be responsible for Patent Expenses and shall have no further right to
UMB’s rights to such UMB Improvement and/or Joint Improvement. 
 3.6.4 Subject to rights of a Third Party which
sponsors the research at UMB as a result of which the Improvement was invented or discovered, Company is hereby granted a first option to receive an exclusive license to UMB’s rights in any Optioned Improvement within the Licensed Field (the
“Option”) during the Option Term; provided, however, that this Agreement is then in effect, there are at that time no uncured defaults or breaches by Company of this Agreement or any other Agreement between Company and
UMB, and Company pays Patent Expenses in accordance with Section 3.6.8. 

  
 12 

 3.6.5 Company may exercise the Option by giving written notice to UMB at any time
within [**] days after Company receives notice from UMB under Section 3.6.2 concerning the particular Optioned Improvement (the “Option Term”). Upon written notice by Company during the Option Term, the Parties shall
negotiate in good faith for a period of [**] days (or such longer period as the Parties may agree) (the “Negotiation Period”) an amendment to this Agreement adding such Optioned Improvement to the Patent Rights set forth on
Schedule A. If an amendment is executed by the Parties, but only in that event, the Optioned Improvement (“Licensed Improvement”) shall be deemed to constitute part of the Patent Rights. The Optioned Improvement shall not be
considered part of Patent Rights unless and until added by such amendment. 
 3.6.6 Any amendment shall provide that the
Licensed Improvement shall be subject to the terms and conditions of this Agreement, including without limitation Article 5 (Consideration). However, (a) if USM bond counsel advises that U.S. tax law relating to tax-exempt bond issues
which financed the construction or renovation of UMB resources used for research related to the Licensed Improvement (including without limitation the “Safe Harbor” provisions of Internal Revenue Procedure 97-14) would be applicable to the
license of the Licensed Improvement, and (b) UMB or USM reasonably determines that the royalty rate set forth in this Agreement as applied to the Licensed Improvement would not satisfy the requirements of that tax law, then the Parties shall
negotiate in good faith to set a commercially reasonable royalty rate that does satisfy those requirements. If the Parties are unable to agree upon a royalty rate for the Licensed Improvement during the Negotiation Period, the Parties shall submit
the issue for dispute resolution pursuant to Section 14.3. 
 3.6.7 If the Negotiation Period ends and the
Parties have not executed an amendment, Company shall have no rights with respect to the Optioned Improvement, shall have no obligation to pay Patent Expenses related to such Optioned Improvement, and UMB may license all or a portion of its interest
in the Optioned Improvement to one or more Third Parties; provided, however that for a period of [**] after the expiration of the Negotiation Period, UMB may only offer the rights to Third Parties on terms and conditions that are not
more favorable than the last offer made by UMB to Company, unless those more favorable terms and conditions have first been offered in writing to Company, and either (a) Company has declined in writing to accept the offer, or (b) Company
has filed to respond to the offer within [**] days after receiving the offer. 
 3.6.8 In consideration for the Option,
Company shall be responsible for payment of all Patent Expenses with respect to Optioned Improvements. If Company fails to pay timely any undisputed invoice for the Patent Expenses, the Option with respect to the relevant Optioned Improvement shall
terminate and be of no further force or effect, effective as of the date of UMB’s written notice of termination. If Company notifies UMB of its intent not to exercise the Option with respect to any particular Optioned Improvement, or does not
timely exercise the Option, Company shall have no obligation to pay Patent Expenses related to the Optioned Improvement which are incurred more than [**] days after UMB’s receipt of the notice or the date of expiration of the applicable Option,
as the case may be. UMB shall use reasonable efforts to minimize the Patent Expenses incurred during the [**] day period. 

  
 13 

 3.6.9 For purposes of this Agreement, inventorship of any Improvement shall be
determined only in accordance with U.S. patent law, notwithstanding that the patent laws of other countries where patent applications are filed may follow rules of inventorship that differ from U.S. patent law. For purposes of this Agreement, an
invention shall be deemed to be “made” when it is conceived. 
 ARTICLE 4. DILIGENCE REQUIREMENTS 

4.1 R&D Plan and Business Plan. 

4.1.1 Company has delivered to UMB prior to execution of this Agreement: (a) a research and development plan (the
“R&D Plan”) to be reasonably acceptable to UMB, showing the amount of money and time budgeted and planned for technical development of the Patent Rights, and (b) a business plan (the “Business Plan”) to be
reasonably acceptable to UMB, showing the proposed commercialization scheme for Licensed Products. 
 4.1.2 Company
shall provide [**] written reports for the first [**] after the Effective Date, and [**] written reports thereafter, to UMB on progress against the R&D Plan and the Business Plan (and any commercially reasonable updates thereto by Company),
including general information on the progress of research and development activities related to the Licensed Products and marketing analyses and the occurrence or satisfaction of each of the due diligence milestones set forth on
Schedule B. Such reports shall contain information sufficient for UMB to determine whether Company is making progress with respect to Licensed Products, but Company shall not be required to disclose detailed or sensitive data or trade
secrets. The reports shall be due within [**] days following the expiration of each reporting period. Any information or reports provided under this Section shall be Company Confidential Information subject to Article 7 (Confidentiality).

 4.2 Licensed Products to Market. Company shall use Commercially Reasonable Efforts to bring one or more Licensed Products to
market as soon as practicable in accordance with the R&D Plan and the Business Plan. “Commercially Reasonable Efforts” means, with respect to the commercialization of a Licensed Product, efforts that are consistent with those
utilized by companies of similar size and type for products with similar commercial potential at a similar stage, taking into consideration their safety and efficacy, their cost to develop, the competitiveness of alternative products, the nature and
extent of their market exclusivity, the likelihood of regulatory approval, their profitability, and all other relevant factors. 
 4.3
Due Diligence Milestones. Company shall timely achieve the due diligence milestones set forth on Schedule B. 
 ARTICLE 5.
CONSIDERATION 
 The Parties acknowledge and agree that each of the payment obligations set forth in this Article 5 have been
established for the convenience of the Parties after due consideration was given to alternative payment structures. Such payment obligations have been deemed by the Parties to be the most appropriate and convenient means of valuing Company’s
right to practice 

  
 14 

 
the Patent Rights under this Agreement and to receive the benefit of UMB entering into this Agreement. In consideration of the license hereunder: 

5.1 License Fee. Within [**] days after the Effective Date, Company shall pay to UMB a non-refundable license fee of Twenty Thousand
Dollars (U.S. $20,000.00). The license fee is not creditable against any other fee, royalty, or payment. 
 5.2 License Maintenance
Fees. Company shall pay license maintenance fees to UMB of Ten Thousand Dollars (U.S. $10,000.00) per annum commencing on the first anniversary of the Effective Date, and continuing on each anniversary of the Effective Date during the Term,
until the year in which the First Commercial Sale occurs. The license maintenance fees are not creditable against any other fee, royalty, or payment. 

5.3 Milestone Payments. Company shall pay to UMB the following milestone payments: 

 

					
	On submission of each IND for a Licensed Product to the U.S. FDA:	  	U.S. $50,000.00	  	Within [**] days following submission
			
	On approval of each NDA or BLA for a Licensed Product by the U.S. FDA:	  	U.S. $100,000.00	  	Within [**] days following receipt of approval

 5.4 Minimum Annual Royalty. Company shall pay UMB guaranteed minimum annual royalties of Fifty
Thousand Dollars (U.S. $50,000.00) per year, beginning with the calendar year following the year in which the First Commercial Sale occurs. The minimum annual royalty for the year of First Commercial Sale shall be pro-rated according to the date of
First Commercial Sale. Company shall pay the minimum annual royalty, if any, due with respect to a calendar year by the next February 1 following that year. Minimum annual royalties shall be creditable against running royalties payable under
Section 5.5. 
 5.5 Running Royalties on Sales of Licensed Products and Combination Products. 

5.5.1 Licensed Products. Subject to the terms of this Section 5.5, Company shall pay to UMB a running
royalty of [**] percent ([**]%) of Net Revenues on Sales of Licensed Products (other than Combination Products) by Company or Sublicensees. 

5.5.2 Combination Products. 

(a) Subject to the terms of this Section 5.5, Company shall pay to UMB a running royalty of [**] percent ([**]%) of
Combination Product Net Revenues (as defined below) on Sales by Company or Sublicensees of Combination Products. “Combination Product Net Revenues” shall be determined as follows: 

(1) by multiplying the Net Revenues of the Combination Product by the fraction A/(A+B), if on a country-by-country basis, the
Covered Component(s) and Non-Covered Component(s) are sold separately in finished form in such country, where A is 

  
 15 

 
the average invoiced sales price of the Covered Component(s) sold separately in finished form in such country and B is the average invoiced sales price of the Non-Covered Component(s) sold
separately in finished form in such country; 
 (2) by multiplying the Net Revenues of the Combination Product by the
fraction C/(C+D), if on a country-by-country basis the Covered Component(s) are sold separately in finished form in such country, but the Non-Covered Component(s) are not sold separately in finished form in such country, where C is the average
invoiced sales price of the Covered Component(s) in finished form in such country and D is the difference between the average invoiced sales price of the Combination Product and the average sales price of the Covered Component(s) in finished form in
such country; 
 (3) by multiplying the Net Revenues of the Combination Product by the fraction 1 minus C/(C+D), if on a
country-by-country basis the Non-Covered Component(s) are sold separately in finished form in such country but the Covered Component(s) are not sold separately in finished form in such country, where C is the average invoiced sales price of the
Non-Covered Component(s) in finished form in such country and D is the difference between the average invoiced sales price of the Combination Product and the average invoiced sales price of the Non-Covered Component(s); or 

(4) if on a country-by-country basis neither the Covered Component(s) nor the Non-Covered Components) are sold separately in
finished form in a country, Combination Product Net Revenues shall be determined by the Parties in good faith based on the relative fully allocated costs of goods for each Covered Component and Non-Covered Component; provided, however,
that if either Party can establish in good faith that using the relative fully allocated costs of goods would not produce a reasonable determination of Combination Product Net Revenues, the matter shall be resolved pursuant to the dispute resolution
procedures set forth in Article 14. 
 5.5.3 Duration. Royalties under Sections 5.5.1 and 5.5.2
shall be payable on a country-by-country and Licensed Product-by-Licensed Product basis commencing with the First Commercial Sale until the later of: (a) the expiration of the last to expire of the Claims of the Patent Rights covering the
manufacture, use or sale of a Licensed Product in such country (the “Claim Expiration Date”), or (b) ten (10) years after the First Commercial Sale of a Licensed Product in such country. However, if the Claim Expiration
Date is earlier than the tenth (10th) anniversary of the First Commercial Sale in such country then, for the period commencing upon the Claim Expiration Date and ending ten (10) years after the First Commercial Sale in such country, the
royalty rate set forth in Section 5.5.1 and 5.5.2 shall be reduced by [**] percent ([**]%) (i.e., to [**] percent ([**]%)). 

5.5.4 Royalty Reduction. UMB and Company shall negotiate in good faith an appropriate reduction in the royalty rate if
Company proves that it suffered a loss of Sales due to competition from a product whose manufacture, use or sale is covered by a UMB-owned patent which was invented by one or more of the Inventors, and is sold by a Third Party under a license from
UMB. 

  
 16 

 5.5.5 Sales to Company Affiliates or Sublicensees. Company shall not be
required to pay royalties on Sales of Licensed Products to a Company Affiliate or Sublicensee, and these Sales shall not be included in Net Revenues on which royalties are calculated. However, if the Company Affiliate or Sublicensee is an end user
of a Licensed Product, these Sales shall be included in Net Revenues of the Licensed Product for the purpose of calculating royalties, at the average selling price charged by Company to Third Parties for the Licensed Product during that same period
and in the relevant country. 
 5.5.6 Royalty Stacking. If Company or a Sublicensee is reasonably required to license
one or more technologies of one or more Third Parties in order to make, have made, use, offer to Sell, Sell or import Licensed Products, and is required to pay a royalty therefor, then up to [**] percent ([**]%) of the royalty may be deducted from
running royalties payable to UMB; provided, however, that the running royalties payable to UMB shall not be reduced by more than [**] percent ([**]%). Company shall not permit any Sublicensee to deduct from Sublicense Income due to
Company more than [**] percent ([**]%) of royalties due as a result of any licenses from one or more Third Parties to that Sublicensee. 

5.6 Sublicense Income. 

5.6.1 Company shall pay to UMB a percentage of all Sublicense Income that is received from each Sublicensee, according to when
the Sublicense is executed, as follows: 
 Prior to the 1st anniversary of the Effective Date: [**]% 

On or after the 1st anniversary but prior to the 2nd anniversary of the Effective Date:
[**]% 
 On or after the 2nd anniversary but prior to the 3rd anniversary of the
Effective Date: [**]% 
 On or after the 3rd anniversary but prior to the 4th
anniversary of the Effective Date: [**]% 
 On or after the 4th anniversary of the Effective Date: 10% 

5.6.2 Any share of a milestone payment from a Sublicensee which is paid to UMB pursuant to this Section may be credited toward
the milestone payments due under Section 5.3. 
 5.6.3 Company shall pay UMB the required share of any Sublicense
Income paid in cash within [**] days of the end of each calendar quarter. 
 5.6.4 For any non-cash Sublicense Income paid in
securities that are publicly traded or otherwise have a value that can be agreed by the Parties at that time, the Parties shall agree on an acceptable method to have UMB’s share paid within [**] days of Company receiving the securities, by
Company either (a) transferring and delivering to UMB the required percentage of the securities, or (b) paying in cash the Fair Market Value of such securities. 

  
 17 

 
Notwithstanding the foregoing, if Company is unable to transfer, deliver, or liquidate the securities within the period without violating an applicable law, regulation, other legal requirement,
or any agreement or other arrangement with any other Person (including the Sublicensee), then Company shall compensate UMB in accordance with the foregoing within [**] days after it is first able to transfer and deliver the securities without such a
violation. UMB shall execute and deliver, prior to any transfer of securities, all commercially reasonable stockholder agreements and other documents applicable to the securities to be transferred to UMB. 

5.6.5 As to any other form of Sublicense Income that cannot be valued as contemplated by this Section 5.6, the
Parties shall negotiate in good faith to arrive at a mutually agreeable solution under which UMB shall receive its required share. 
 5.7
Payments For Net Revenues in Foreign Countries. 
 5.7.1 Royalties are payable from the country in which they are
earned and are subject to foreign exchange regulations then prevailing in the country. Royalty payments must be paid to UMB in U.S. Dollars by check(s) drawn to the order of UMB or by electronic funds transfers to an account designated by UMB. To
the extent Sales are made in a foreign country, those royalties shall be determined first in the currency of the country in which the royalties are earned, and then converted to their equivalent in U.S. Dollars. The buying rates of exchange for
converting the currencies involved into the currency of the U.S. quoted by the Morgan Guaranty Trust Company of New York, New York (or any successor), averaged on the last business day of each of six (6) consecutive calendar months constituting
the period in which the royalties were earned, shall be used to determine any conversion. Company shall bear any loss of exchange or value or pay any expenses incurred in the transfer or conversion to U.S. dollars. 

5.7.2 If any applicable law or regulation (including without limitation currency exchange regulations) prevents or limits
royalty payments with respect to Net Revenues in any country, Company shall render to UMB annual reports of Sales of Licensed Products in that country. All monies due and owing UMB as provided in the annual reports shall, at UMB’s option:
(a) be deposited promptly in a local bank in that country in an account to be designated by UMB in writing; or (b) be paid promptly to UMB or deposited in its account, as directed in writing by UMB in any other country where the payment or
deposit is lawful. 
 ARTICLE 6. PATENT PROSECUTION AND PUBLICATIONS 

6.1 Patent Prosecution. 

6.1.1 UMB is solely responsible for preparing, filing, prosecuting (including without limitation defense of the applications in
an interference proceeding), and maintaining the Patent Rights. 
 6.1.2 UMB shall prepare and file patent applications for
the Patent Rights in the U.S., and in other countries as set forth in Section 6.2. 

  
 18 

 6.1.3 UMB is solely responsible for selection of patent counsel and for matters
regarding the scope and content of U.S. and foreign patent applications and other filings. UMB shall not seek to substantially narrow the scope of or irrevocably abandon a pending application or an issued patent without obtaining Company’s
written consent. 
 6.1.4 Each Party shall consult with the other Party as to the filing, prosecution and maintenance of the
Patent Rights reasonably prior to any deadline or action with the U.S. Patent and Trademark Office or any foreign patent office, and shall furnish the other Party with copies of all relevant documents reasonably in advance of the consultation. Each
Party will wherever commercially and legally reasonable incorporate any comments requested by the other Party, and will provide reasonable justification if it determines not to incorporate such comments. Each Party shall cooperate with the other
Party in connection with the prosecution, filing, and maintenance of any Patent Rights. Each Party shall advise the other Party reasonably promptly as to material developments with respect to the Patent Rights. 

6.1.5 Neither Party shall be liable for any loss, as a whole or in part, of a patent or patent term extension granted by the
U.S. Patent and Trademark Office (or any foreign patent office) on a patent included in the Patent Rights, including without limitation if the loss results from acts or omissions of outside patent counsel retained by a Party. 

6.1.6 At UMB’s or Company’s option, Company shall be responsible for defense of any issued patent regarding the
Patent Rights in an interference proceeding, at Company’s sole expense. 
 6.2 Foreign Patent Prosecution. 

6.2.1 UMB shall prepare and file patent applications for Patent Rights in Japan, Australia, Canada, the European States, and in
those additional countries which are specified by Company in accordance with this Section. No later than [**] days before the applicable national phase filing deadline Company shall specify in writing to UMB the additional foreign countries in which
patent applications for Patent Rights are to be filed and prosecuted. 
 6.2.2 UMB may elect to file and prosecute patent
applications, at its own expense, in any foreign country not specified under Section 6.2.1, or as to which Company has declined or failed to pay Patent Expenses. If UMB so elects, as to any such country Company shall have: no right to
give input into patenting strategy or decisions; no license rights with respect to Patent Rights; and no Option rights with respect to Improvements. 

6.2.3 Upon at least [**] days prior written notice to UMB, Company may elect to discontinue payment of Patent Expenses in any
country, provided however that Company shall consult with UMB regarding the election to discontinue payment of Patent Expenses with respect to any particular Patent Right in the U.S., Japan, Australia, Canada, U.K., France, Germany and Spain but in
no event shall Company, without the consent of UMB, elect to discontinue payment of Patent Expenses with respect to all Patent Rights in the U.S., Japan, Australia, Canada, U.K., France, Germany or Spain. Company shall be responsible for reasonable
Patent Expenses incurred during the [**] day period with respect to the country or countries where Company is 

  
 19 

 
discontinuing payments. At the end of the [**] day period, Company’s rights in Patent Rights shall terminate with respect to the country or countries, and Company shall execute documents as
reasonably may be requested by UMB to confirm termination of Company’s rights. 
 6.3 Patent Expenses. Company
shall be solely responsible for all Patent Expenses incurred before the Effective Date (to the extent not reimbursed to UMB by a Third Party) and during the Term. Company shall pay each undisputed invoice for Patent Expenses in full within [**] days
after the date of invoice. Company’s failure to pay any undisputed invoice on time shall result in a loss of input into patenting decisions until the failure is cured, together with accrued interest and late fees, if any. 

6.4 Publication. UMB (through TEC-COM) shall request UMB Personnel not to publish or otherwise publicly disclose the
results of research relating to the Patent Rights within the Licensed Field, unless any materials containing those results are first submitted to TEC-COM for review, comment, and consideration of appropriate patent action. UMB shall request that UMB
Personnel submit any materials to TEC-COM for review at least [**] days prior to the date of the planned submission for written publication or planned public disclosure. UMB shall forward such material to Company. Company shall advise TEC-COM within
[**] days after receipt of the materials whether patent applications should be filed in connection with obtaining or maintaining Patent Rights related to the materials. TEC-COM shall request UMB Personnel to delay written publication or public
disclosure up to a maximum of [**] days after the date Company receives the materials to enable TEC-COM to file, at Company’s expense, any patent applications recommended by Company. 

ARTICLE 7. CONFIDENTIALITY. 
 7.1
General Restrictions on Use and Disclosure. 
 7.1.1 Each Party may disclose to the other certain Confidential
Information. Confidential Information may be used or disclosed by the Receiving Party only in accordance with the provisions of this Article. The Receiving Party shall use that level of care to prevent the use or disclosure of the Disclosing
Party’s Confidential Information as it exercises in protecting its own Confidential Information. 
 7.1.2 Each Party may
disclose or use Confidential Information if: (a) with respect to Company as the Receiving Party, the disclosure or use is reasonably necessary to exercise the license granted hereunder; or (b) with respect to UMB as the Receiving Party,
the use is reasonably necessary to determine compliance with the terms of this Agreement, or (c) the disclosure or use is reasonably necessary to fulfill or comply with requirements of governmental authorities having jurisdiction, including
without limitation the Securities and Exchange Commission, National Institutes of Health, FDA and U.S. Patent and Trademark Office. 

7.1.3 The Receiving Party shall not disclose or use the Confidential Information for a period of [**] years after receipt,
other than as expressly set forth in this Agreement. 
 7.1.4 Any Confidential Information that would identify human research
subjects or patients shall be maintained confidentially in accordance with applicable law. 

  
 20 

 7.1.5 Any permitted disclosure or use of Confidential Information shall be made
only to those individuals who have a need to know and who are subject to written confidentiality restrictions consistent with those set forth in this Article. 

7.2 Exceptions. These obligations of non-disclosure and nonuse do not apply to the extent to which the Receiving Party can demonstrate
by reliable written evidence that: 
 7.2.1 The Confidential Information was or becomes generally available to the public
(other than through a breach of this Agreement, a confidential disclosure agreement, any other agreement, or applicable law, and not due to any unauthorized act by the Receiving Party); 

7.2.2 The Confidential Information was already in the possession of the Receiving Party at the time of the disclosure (other
than pursuant to a confidential disclosure agreement between the Parties and not due to any unauthorized act by the Receiving Party); and 

7.2.3 The Confidential Information was developed by the Receiving Party independent of and with no reliance upon the Disclosing
Party’s Confidential Information. 
 In addition, the Receiving Party may disclose Confidential Information to the extent necessary to
comply with applicable laws or regulations, or with a court or administrative order, provided that the Disclosing Party receives prior written notice of such disclosure, to the extent reasonably possible, and that the Receiving Party takes all
reasonable and lawful actions to obtain confidential treatment for such disclosure and, to the extent possible, to minimize the extent of such disclosure. 

7.3 Markings and Legends. All Confidential Information shall be clearly marked as confidential by the Disclosing Party. If the
Confidential Information is not in written or tangible form when disclosed, it shall be indicated as confidential upon disclosure and then summarized in writing and so marked as confidential within [**] days after disclosure to the Receiving Party.

 7.4 UMB Standards and Practices. UMB is an educational institution with standards and practices for protection of Confidential
Information which differ from Company’s standards and practices. UMB shall only be required to use reasonable efforts to protect the confidentiality of Company Confidential Information in a manner consistent with the standards and practices
used by UMB to protect its own Confidential Information. Provided that those efforts are made, Company agrees not to seek to hold UMB or UMB Personnel liable in the event of disclosure or use of Company Confidential Information. 

7.5 Maryland Access to Public Records Law. The records of UMB are subject to the Maryland Access to Public Records Law(Title 10,
Subtitle 6, Part III, State Government Article, Annotated Code of Maryland) (the “Act”). This Agreement and its Schedules and Exhibits (whether or not made part of this Agreement) and reports to UMB pursuant to Article 8 are
public records of UMB. Company takes the position that any Company Confidential Information provided to UMB under this Agreement is confidential financial, commercial, or trade secret information, not subject to disclosure as provided in
Section 10-617(d) of the Act. Unless UMB determines on the advice of counsel that Company’s position is not reasonable, 

  
 21 

 
UMB agrees to assert that position in response to any request for public records applicable to Company Confidential Information, and to promptly notify Company upon receipt of a request so that
the Company may seek to preserve the confidentiality of Confidential Information. 
 ARTICLE 8. REPORTS, PAYMENTS, AND ACCOUNTING 

8.1 Audits. During the term of this Agreement and for [**] years after its expiration or termination, Company shall keep (and
shall require each Sublicensee to keep) complete, true, and accurate records containing all the particulars that may be necessary to determine royalties, fees, Patent Expenses, or other amounts payable to UMB. The records shall be subject to
inspection at any time during regular business hours upon reasonable notice (but not more than [**]) by an independent auditor appointed by UMB for this purpose and reasonably acceptable to Company. The auditor shall report to UMB only the amount of
royalties, fees, Patent Expenses, or other amounts payable under this Agreement. This audit shall be at UMB’s expense; provided, however, if the audit shows an underpayment of [**] percent ([**]%) or more for any period, the audit
expense shall be borne by Company. 
 8.2 Reports. Within [**] days after the close of each calendar quarter, Company shall
deliver to UMB a true and accurate report, giving particulars of the business conducted by Company and Sublicensees, if any, in the preceding period that are pertinent to any accounting for royalties, fees, Patent Expenses, or other payments payable
under this Agreement. These reports shall be certified as correct by an authorized officer of Company and shall include at least the following for the period: 

8.2.1 Number of Licensed Products (including Combination Products) sold by Company and Sublicensees; 

8.2.2 Net Revenues (including the deductions as provided in the definition of Net Revenues) for Licensed Products (including
Combination Products) received by Company and Sublicensees and the aggregate Sublicense Income received by Company; and 

8.2.3 Data used to calculate Combination Product Net Revenues for Sales of Combination Products. 

8.2.4 Names and addresses of all Company Affiliates practicing the Patent Rights, and names and addresses of all Sublicensees.

 8.3 Payment with Report. With each report submitted in accordance with Section 8.2, Company must pay to UMB the
royalties, fees, or other payments due and payable under this Agreement for the period covered by the report. If no royalties, fees or other payments are due, Company shall so report. 

8.4 Due Diligence Milestones. Company shall report in writing to UMB no later than [**] days following the occurrence or satisfaction
of each of the due diligence milestones set forth on Schedule B. Company shall make milestone payments due upon achievement of the items set forth in Section 5.3. 

  
 22 

 8.5 Interest on Late Payments. Interest is due on any payment to UMB required under this
Agreement that is more than [**] days late, and on any underpayment of royalties or other amounts payable under this Agreement. The interest rate is [**]% simple interest per month accruing from the due date. 

8.6 Taxation. UMB is a unit of the government of the State of Maryland, and therefore is exempt from taxation. Company shall assert to
all applicable governmental authorities that UMB is exempt from tax by virtue of its governmental status. If Company nevertheless is required to withhold tax on royalties or other payments due to UMB under this Agreement, it shall pay promptly any
tax to the appropriate governmental authority. In that event, it shall furnish UMB with proof of payment of the tax together with official or other appropriate evidence issued by the competent governmental authority sufficient to enable UMB to
support a claim for tax exemption, credit, or refund with respect to any sum so withheld. Company shall cooperate with UMB if UMB elects to seek, at its own expense, administrative or judicial determination of tax exemption, credit, or refund. 

ARTICLE 9. INFRINGEMENT 
 9.1
Notification. Each Party shall promptly notify the other if it has knowledge of or reasonable grounds to suspect any infringement of any Claim of the Patent Rights, or of any misuse, misappropriation, theft, or breach of confidence related to
the Patent Rights (collectively, an “Infringement”). 
 9.2 Company’s Right to Sue Infringers; Defense of Third
Party Claims. 
 9.2.1 Company shall have the first right, but not the obligation, to bring suit for any Infringement in
its own name, at its own expense, and on its own behalf. If required by law, UMB shall permit any action under this Section to be brought in its name including being named as a party-plaintiff; provided, however: 

(a) It is necessary in the reasonable opinion of Company’s counsel and the Office of the Attorney General of Maryland to
achieve standing or otherwise avoid dismissal of the suit; 
 (b) UMB is not the first named party in the action (to the
extent this can be controlled by the Company and, in the reasonable opinion of Company’s counsel, will not affect the ability to bring suit); and 

(c) The pleadings and any public statements about the action state that Company is pursuing the action and that Company has the
right to join UMB as a party (only to the extent, in the reasonable opinion of Company’s counsel, such statements in the pleadings or in public will not affect the ability to bring suit). 

9.2.2 If a declaratory judgment action alleging invalidity or non-infringement of any of the Patent Rights is brought against
Company or raised by way of counterclaim or affirmative defense in an infringement suit brought by Company under Section 9.2.1. Company 

  
 23 

 
shall have the first right, but not the obligation, to defend the suit in its own name, at its own expense, and on its own behalf. 

9.3 Litigation Expenses; Recoveries. 

9.3.1 In any action under Section 9.2 Company shall be responsible for all litigation expenses, including without
limitation costs, fees, expert witness fees, attorney fees, and disbursements. Up to [**]%) of the expenses may be credited against the running royalties payable on Sales in the country in which the suit is filed. Any amount which exceeds the amount
of running royalties payable on Sales in that country in any year may be carried over as a credit on the same basis in succeeding years. 

9.3.2 Any recovery by Company of compensatory or actual damages (including without limitation damages awarded to compensate for
lost profits or lost sales due to infringing sales, price erosion due to infringing sales, diminution of value of Licensed Products, or lost sales of unpatented related products) shall be treated as Net Revenues, and Company shall pay royalties
thereon to UMB. 
 9.3.3 Any recovery by Company of punitive, special, incidental, consequential, indirect, or other
non-compensatory damages (including without limitation treble damages for willful infringement under Section 284 of the Patent Act, or attorney’s fees under Section 285 thereof), first shall be applied to reimburse UMB for credits
against running royalties under Section 9.3.1, and then to reimburse Company for its unreimbursed litigation expenses. Any remaining amount from this recovery shall be shared equally by Company and UMB. 

9.4 UMB’s Rights to Sue or Intervene. 

9.4.1 If Company fails to bring suit under Section 9.2.1 by any required filing deadline (but not later than [**]
months after receiving notice or otherwise having knowledge of Infringement), UMB shall have the right, but not the obligation, to initiate a suit. If Company fails to timely notify UMB of its intent to respond in opposition to a legal action under
Section 9.2.2 within [**] days after Company’s receipt of notice of the filing of the action, or if Company notifies UMB that it does not intend to oppose the action, UMB shall have the right, but not the obligation, to respond to
the action at its own expense. In addition, UMB shall have a continuing right to intervene in any action described in Section 9.2.1 or 9.2.2. 

9.4.2 Notwithstanding anything herein to the contrary, if UMB files suit, responds to a legal action, or otherwise intervenes
pursuant to Section 9.4, UMB shall be responsible for its own litigation expenses and shall be entitled to all recoveries which it obtains for itself in connection therewith. 

9.5 Conduct of Suit. 

9.5.1 Company shall diligently pursue any suit or action under Section 9.2.1 or 9.2.2. Company shall keep
UMB reasonably apprised of all developments in the suit. Company shall not prosecute, defend, settle, or otherwise compromise any suit in a manner that materially 

  
 24 

 
adversely affects the scope, validity, or enforceability of the Patent Rights without UMB’s prior written consent, which consent shall not be unreasonably withheld or delayed. 

9.5.2 If the Parties so agree, they may institute suit jointly. In that event, they will prosecute the suit in both their
names; bear the out-of-pocket litigation expenses equally; share any recovery or settlement equally; and negotiate in good faith regarding how they will exercise control over the action. 

9.5.3 Each Party shall cooperate fully with the other Party in connection with any action under this Article. Each Party shall
provide prompt access to all necessary documents and shall render reasonable assistance in response to requests by the other Party. 

9.5.4 Any Party which commences a suit and then wants to abandon it, shall give timely notice to the other Party. The other
Party may continue prosecution of the suit, in which event the Parties shall negotiate in good faith regarding the sharing of expenses and any recovery in the suit. 

9.5.5 UMB shall not be liable for any losses incurred as a result of an action for infringement brought against Company as a
result of Company’s actions or omissions, including without limitation its exercise of any right granted under this Agreement. 

ARTICLE 10. TERM AND TERMINATION 

10.1 Term and Expiration. This Agreement shall commence as of the Effective Date. Unless sooner terminated in accordance with this
Article, this Agreement shall expire on a country-by-country basis as of the later of: (a) the date of expiration of the last to expire of the Claims of the Patent Rights in such country, or (b) ten (10) years after the First
Commercial Sale of a Licensed Product in that country (the “Term”). 
 10.2 Termination by UMB. 

10.2.1 Failure To Pay. In the event of a default or failure by Company to pay UMB any sum due and payable under this
Agreement, UMB may terminate this Agreement and the license(s) granted under this Agreement, if the default or failure is not cured within [**] days of receiving written notice thereof from UMB. 

10.2.2 Diligence Default. In the event of any default or material breach of Section 4.3 (Due Diligence
Milestones), UMB may terminate this Agreement and the licenses granted under this Agreement if the default or breach is not cured within [**] days of receiving written notice thereof from UMB. The withholding by a regulatory agency of marketing or
other approval in spite of Company’s Commercially Reasonable Efforts to obtain the approval shall not constitute a default or material breach of Section 4.3 (Due Diligence Milestones). 

10.2.3 Other Default or Material Breach. In the event of any default or material breach of this Agreement by Company
(other than under another subsection of this Section 10.2), UMB may terminate this Agreement and the license(s) granted under this Agreement, if the default or breach is not cured within [**] days of written notice thereof;
provided, however, that 

  
 25 

 
if any default or breach cannot be cured by the exercise of due diligence within [**] days, then the time for cure shall be extended for the time reasonably necessary to effect the cure (the
extension not to exceed [**] days), provided that Company promptly commences to cure within said period and at all times thereafter proceeds diligently to cure the default or breach. 

10.2.4 Bankruptcy. UMB may terminate this Agreement and the license granted hereunder if Company: (a) makes a
general assignment for the benefit of creditors; (b) commences a case under or otherwise seeks to take advantage of any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution, or liquidation law, statute, or proceeding;
(c) by any act indicates its consent to, approval of, or acquiescence in any proceeding or the appointment of a receiver of or trustee for it or a substantial part of its property, or suffers any receivership, trusteeship, or proceeding to
continue undismissed for a period of thirty (30) days; or (d) becomes a debtor in any case under any chapter of the U.S. Bankruptcy Code. 

10.3 Termination by Company. If Company determines at any time that a license under the Patent Rights in any particular country shall
no longer be advantageous to Company’s commercial success, then Company may terminate this Agreement as to that country. In that event, Company shall provide UMB with thirty (30) days advance written notice of termination, and shall pay to
UMB all payments due through the effective date of the termination with respect to that country, including without limitation royalties, fees, and Patent Expenses. 

10.4 Survival. Expiration or termination of this Agreement does not relieve either Party of any obligation which arises before
expiration or termination. Articles 5, 7, 8, 10, 13, and 14 shall survive expiration or termination, and shall expire in accordance with their terms, if any. Other Sections of this Agreement shall survive
and be effective after expiration or termination where that intent is clear from the content of those Sections. 
 10.5 Effect of
Termination. Upon expiration or termination of this Agreement in whole or in part for any reason: 
 10.5.1 On or before
the effective date of expiration or termination, Company shall pay to UMB all amounts due hereunder, including without limitation royalties, fees, and Patent Expenses; 

10.5.2 Company shall be obligated to pay Patent Expenses incurred during a [**] day period following the effective date of
termination or expiration, provided that UMB shall use reasonable efforts to minimize the Patent Expenses incurred during that period; 

10.5.3 Company shall return all UMB Confidential Information to UMB, together with all copies and other forms of reproduction,
except that a single archive copy may be kept in Company’s legal files subject to the terms of this Agreement; 
 10.5.4
UMB shall return all Company Confidential Information in the actual possession of TEC-COM to Company, together with all copies and other forms of reproduction, except that a single archive copy may be kept in UMB’s legal files subject to the
terms of this Agreement; 

  
 26 

 10.5.5 Each Party shall execute and deliver any agreements, instruments, and
documents as are reasonably necessary or appropriate to carry out the terms and conditions of this Section; and 
 10.5.6 UMB
agrees that any Patent Rights sublicensed by Company to a Sublicensee shall become directly licensed from UMB to the Sublicensee in accordance with Section 3.4. 

ARTICLE 11. MISCELLANEOUS AGREEMENTS 

11.1 Non-Solicitation of UMB Personnel. 

11.1.1 Company shall not knowingly employ or compensate, directly or indirectly, any Person working on matters related to the
Patent Rights (including but not limited to UMB Personnel) or involved in negotiating this Agreement on behalf of UMB, while the Person is employed by UMB or for [**] years thereafter, unless UMB provides Company with prior written consent of the
UMB President to the employment or compensation by Company. “Compensation” includes but is not limited to: stock option or stock purchase agreements, consulting agreements, any other form of agreement, and cash payments.
“Employment” includes both uncompensated and compensated service to Company. The Maryland Public Ethics Law (Title 15, State Government Article, Annotated Code of Maryland) may apply to a decision by the UMB President in regard to
the matter. 
 11.1.2 This Section 11.1 is not intended to prevent or allow an Inventor to own stock of Company
received by Inventor as a distribution of licensing revenues under the USM IP Policy. As a Company shareholder, an Inventor may receive dividends and enjoy other benefits of stock ownership, subject to any terms and conditions UMB may require in
order to satisfy conflict of interest concerns or the Maryland Public Ethics Law. This provision is not intended to prevent Company from placing any reasonable restrictions upon Inventor’s stock that may be necessary to satisfy federal or state
laws or regulations applicable to Company or to development or commercialization of Licensed Products. 
 11.2 Clinical Trials. If
Company conducts clinical trials of a Licensed Product, it shall reasonably consider using UMB, the University of Maryland Medical System Corporation, or other UMB Related Organizations as a site for clinical trials, subject to agreement on terms
and conditions, including compensation, to be negotiated in good faith. Policies of UMB and/or the University System of Maryland may prevent or limit participation of UMB Personnel in the clinical trials. 

11.3 Use of Names. Neither Party shall use the name of the other or any of its Personnel, or any adaptation thereof, in any
advertising, promotional, or sales literature without prior written consent obtained from the other Party. Either Party may publicize the fact that the Parties have entered into this Agreement. 

11.4 Patent Marking. Company shall cause “Patent Pending,” the Patent Rights patent number, or other patent markings to
appear on all Licensed Products, their labels or their 

  
 27 

 
packaging to the extent required by and in accordance with the law in each country where Licensed Products are sold or offered for sale. 

11.5 Inspection. Company shall allow UMB to inspect, at any time during regular business hours and upon reasonable notice, all Company
correspondence to and from the FDA and any other applicable U.S. regulatory agency, and any foreign equivalent related to Licensed Products. 

ARTICLE 12. REPRESENTATIONS AND WARRANTIES 

12.1 By UMB. UMB hereby represents that to the actual knowledge of TEC-COM, as of the Effective Date: 

12.1.1 As confirmed by assignments from UMB Personnel who are known by TEC-COM to be inventors of the Inventions, UMB has full
right, title, and interest in and to the Patent Rights, subject to any rights of the U.S. under grants to UMB and Federal Patent Policy; 

12.1.2 The Patent Rights are not the subject matter of any currently pending litigation involving UMB, and TEC-COM has no
actual knowledge of any related litigation contemplated either by UMB or any Third Party; 
 12.1.3 No Person disputes
ownership of Patent Rights as described in this Agreement; 
 12.1.4 The execution, delivery and performance of this
Agreement and the transactions contemplated hereby have been duly approved; this Agreement has been properly executed by authorized officers of UMB; and this Agreement is the valid and binding obligation of UMB and is enforceable in accordance with
its terms, except as enforceability may be limited by applicable bankruptcy, reorganization, insolvency, and similar laws affecting the rights of creditors generally, general principles of equity, and Maryland law with regard to actions in contract
against the State of Maryland; 
 12.1.5 The execution, delivery and performance of this Agreement do not violate any
agreement to which UMB is a party, or any order, judgment, or decree applicable to UMB; and 
 12.1.6 No consent, approval,
or authorization of, or designation, declaration, or filing with any governmental authority or other Person, is required on the part of UMB in connection with the execution, delivery, or performance of this Agreement. 

12.2 Disclaimer of Warranties by UMB. 

12.2.1 UMB EXPRESSLY DISCLAIMS ALL IMPLIED OR EXPRESS WARRANTIES, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR PATENT VALIDITY, WITH RESPECT TO PATENT RIGHTS, UMB 

  
 28 

 
CONFIDENTIAL INFORMATION, OR LICENSED PRODUCTS CONTEMPLATED BY THIS AGREEMENT. 

12.2.2 UMB DOES NOT WARRANT THE VALIDITY OF THE PATENT RIGHTS OR THE RELIABILITY OR ACCURACY OF UMB CONFIDENTIAL INFORMATION
AND MAKES NO REPRESENTATIONS WHATSOEVER WITH REGARD TO THE SCOPE OF THE PATENT RIGHTS, OR THAT PATENT RIGHTS MAY BE EXPLOITED BY COMPANY OR ITS SUBLICENSEES WITHOUT INFRINGING OTHER PATENTS. 

12.3 By Company. Company hereby represents and warrants to UMB as of the Effective Date that: 

12.3.1 Company is a corporation duly organized, validly existing, and in good standing under the laws of the State of Delaware,
and Company has all requisite corporate power and authority to own, operate, and lease its properties, to carry on its business as now being conducted and as contemplated by this Agreement, to enter into this Agreement, and to carry out the
transactions contemplated hereby; 
 12.3.2 Company’s directors have duly approved the execution, delivery and
performance of this Agreement and the transactions contemplated hereby; this Agreement has been properly executed by the duly-authorized officers of Company; and this Agreement is the valid and binding obligation of Company and is enforceable in
accordance with its terms, except as the enforceability may be limited by applicable bankruptcy, reorganization, insolvency, and similar laws affecting the rights of creditors generally, and general principles of equity; 

12.3.3 The execution, delivery and performance of this Agreement do not violate the terms of Company’s organizational
documents, any agreement to which Company is a party, or any order, judgment, or decree applicable to Company; 
 12.3.4 No
consent, approval, or authorization of or designation, declaration, or filing with any governmental authority or other Person is required on the part of Company in connection with the execution, delivery or performance of this Agreement, except as
specifically set forth herein; 
 12.3.5 Company is not a party to any agreement or instrument or subject to any charter or
other corporate restriction or any judgment, order, writ, injunction, or, to Company’s knowledge, any rule or regulation which materially and adversely affects the operations, prospects, properties, assets, or condition (financial or otherwise)
of Company; 
 12.3.6 No suit, action, litigation, administrative proceeding, arbitration proceeding, governmental
proceeding, investigation, inquiry, or other proceeding is pending or, to the best of Company’s knowledge, threatened against Company which would materially and adversely affect the operations, prospects, properties, assets, or condition
(financial or otherwise) of Company; 

  
 29 

 12.3.7 To the best of Company’s knowledge, Company has fully complied with
all federal, state, and local laws, rules, regulations, and administrative directives which apply to or materially affect the conduct and operation of its business; and 

12.3.8 Company qualifies as a small entity that meets the size standards set forth in 37 C.F.R. §1.27 to be eligible for
reduced patent fees, and Company shall promptly provide written notice to UMB if it has knowledge that Company no longer qualifies as a small entity. 

ARTICLE 13. CLAIMS, INDEMNIFICATION, AND INSURANCE 

13.1 Maryland Tort Claims Act. UMB and UMB Personnel acting within the scope of their employment are subject to the Maryland Tort
Claims Act (Title 12, Subtitle 1, State Government Article, Annotated Code of Maryland) which permits claims in tort against the State of Maryland under certain circumstances and subject to limits provided by law. 

13.2 Sovereign Immunity. Nothing in this Agreement shall be interpreted as: (a) a denial to either Party of any remedy or defense
available to it under the laws of the State of Maryland or Federal law; (b) the consent of the State of Maryland or its agencies and agents to be sued; or (c) a waiver of sovereign immunity or any other governmental immunity of the State
of Maryland and UMB beyond the extent of any waiver provided by law. 
 13.3 Company’s Insurance. 

13.3.1 Company shall maintain during the Term comprehensive liability insurance coverage in the following minimum amounts per
policy period: 
 (a) Comprehensive general liability (including product liability): $[**] per claim and $[**] aggregate;

 (b) Property damage: $[**] per claim; $ [**] aggregate. 

13.3.2 Company warrants that its liability insurance covers contractually assumed liabilities referred to in
Section 13.4, and agrees to maintain the coverage throughout the Term. A certificate evidencing the required insurance coverage shall be delivered to UMB: (a) on or before execution of this Agreement; (b) each time there is a
material change in Company’s insurance coverage; and (c) each time Company’s insurance coverage is renewed. Company agrees to require its insurance carrier(s) to notify UMB within [**] days prior to cancellation of Company’s
insurance coverage. If Company’s liability insurance is written on a claims-made basis (rather than on an occurrence basis), Company shall purchase extending reported coverage or otherwise provide insurance satisfying its obligations hereunder
for a period of not less than [**] years following termination or expiration of this Agreement. 
 13.4 Indemnification by Company.

 13.4.1 Company agrees to defend, indemnify, and hold harmless the State of Maryland, University System of Maryland, UMB,
UMB Related Organizations, their Personnel and regents, students, and trainees (each individually a “Licensor Party” and all, collectively 

  
 30 

 
“Licensor Parties”) against any and all claims, costs or liabilities, including attorney’s fees, expert witness fees, and court costs at trial and appellate levels, for any
loss, damage, personal injury, or loss of life: 
 (a) Caused by the action or omission under this Agreement of Company,
Sublicensees, or their Personnel or any Third Party acting on behalf of or under authorization from Company or a Sublicensee; 

(b) Arising out of use of the Patent Rights by Company, Sublicensees, or their Personnel or by any Third Party acting on behalf
of or under authorization from Company or a Sublicensee; or 
 (c) Arising out of use by a Licensor Party of products,
processes, or protocols developed by Company, Sublicensees, or their Personnel, or by any Third Party acting on behalf of or under authorization from Company or a Sublicensee using Patent Rights, provided the use was consistent with any protocols or
supervision provided directly to a Licensor Party by Company or a Sublicensee. 
 13.4.2 The agreement to defend, indemnify
and hold harmless a Licensor Party is conditioned upon: (a) a Licensor Party promptly notifying Company in writing after Licensor Party receives notice of any claim; and (b) the Licensor Party cooperating with Company in the defense of the
claim. 
 13.4.3 The agreement to defend, indemnify and hold harmless a Licensor Party shall not apply to the extent that any
claim, cost, or liability was proximately caused by the negligent act or willful misconduct of the Licensor Party. 
 ARTICLE 14. DISPUTE
RESOLUTION 
 14.1 Negotiation. If a dispute between the Parties related to this Agreement arises, either Party, by notice to the
other Party, may have the dispute referred to the Parties’ respective officers designated below, or their successors, for attempted resolution by good faith negotiations within [**] days after the notice is received. The designated officers are
as follows: 
 For Company:             President and CEO 

For UMB:                   Vice President, Research
and Development 
 14.2 Mediation. In the event the designated officers are not able to resolve the dispute within this [**] day
period, or any agreed extension, they shall confer in good faith with respect to the possibility of resolving the matter through mediation with a mutually acceptable Third Party or a national mediation organization. If the Parties agree to attempt
to resolve the matter through mediation, they shall participate in any mediation sessions in good faith in an effort to resolve the dispute in an informal and inexpensive manner. All expenses of the mediator shall be shared equally by the Parties.

  
 31 

 14.3 Disputes Regarding Valuation. Any dispute regarding valuation under this Agreement
(including without limitation Sections 3.6.3 or 5.6) which is not timely resolved through the dispute resolution procedures of this Article 14 shall be submitted to a national independent certified public accounting firm or
other independent expert in valuation, to be appointed by mutually agreement of UMB and Company. The costs and expenses of the valuation consultant shall be shared equally by UMB and Company. 

14.4 Statute of Limitations: Admissibility of Evidence. Any applicable statute of limitations shall be tolled during the pendency of a
dispute resolution procedure initiated under this Agreement. Evidence of anything said or any admission made in the course of any dispute resolution procedure shall not be admissible in evidence in any civil action between the parties. In addition,
no document prepared for the purpose of, or in the course of, or pursuant to, the dispute resolution procedure, or copy thereof, shall be admissible in evidence in any civil action between the parties. However, the admissibility of evidence shall
not be limited if all parties who participated in the dispute resolution procedure consent to disclosure of the evidence. 
 ARTICLE 15.
NOTICES AND INVOICES 
 15.1 Notices. Notices under this Agreement shall be in writing and shall be delivered personally as proven by
a signed receipt, sent by a reputable, national overnight delivery service, charges prepaid, or sent by certified mail return receipt requested. Notices shall be addressed to a Party at the address specified below, or at such other place or places
as shall from time to time be specified in a notice similarly given. All notices shall be effective upon receipt. 
  

			
	If to UMB:	  	 If to Company:
  

	 Director, Technology Commercialization
 Office
of Research and Development
 University of Maryland, Baltimore

515 West Lombard Street, Suite 400
 Baltimore, Maryland 21201
-1602
  
	  	 Tokai Pharmaceuticals, Inc.
 1 Broadway, 14th
Floor
 Cambridge, MA 02142
 Attn: President and
CEO

	 Copy to:
  
	  	Copy to:
	 University Counsel
 University of Maryland,
Baltimore
 520 West Lombard Street
 East Hall, Suite 200

Baltimore, Maryland 21201-1627
	  	 Marcia H. Anderegg
 Edwards Angell Palmer &
Dodge LLP
 111 Huntington Avenue at Prudential Center
 Boston,
Massachusetts 02199-7613

 15.2 Invoices. Invoices to Company under this Agreement may be sent to the following address or at such
other place or places as shall from time to time be specified in a notice similarly given: 
 Tokai Pharmaceuticals, Inc.

 1 Broadway, 14th Floor 

  
 32 

 Cambridge, MA 02142 

Attn: Finance Department 

15.3 Changes of Address. Each Party shall at all times keep the other Party informed of its current address. Each Party shall promptly
notify the other Party of any change specifying such changed address for the delivery of notices or invoices. 
 ARTICLE 16. ASSIGNMENT 

16.1 General. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives,
successors, and permitted assigns. Any reference in this Agreement to a Party shall be deemed to include that Party’s successors and permitted assigns. Any purported assignment in violation of this Section shall be null and void. 

16.2 Assignment by Company. 

16.2.1 Company may not assign its rights and obligations under this Agreement without the prior written consent of UMB, which
consent shall not be unreasonably withheld or delayed. 
 16.2.2 Notwithstanding the foregoing, Company may, without consent,
assign this Agreement and its rights and obligations hereunder to an Affiliate or in connection with the transfer or sale of all or substantially all of the assets of the portion of Company’s business to which this Agreement relates, or
Company’s merger, consolidation, or change in control or similar transaction; provided, however, that the purported assignee as of the date of assignment: (a) is not in default of its material obligations under any agreement
with UMB, USM, or the State of Maryland, and is current on all of its material financial obligations to UMB, USM, or the State of Maryland (including without limitation taxes); and (b) is not an adverse party in any litigation, arbitration,
administrative or other similar proceeding with UMB or USM. 
 16.2.3 Company shall give UMB written notice identifying the
prospective assignee at least [**] Business Days prior to the closing of the transaction. Any permitted assignee shall assume in writing all accrued and prospective obligations of Company under this Agreement. No assignment shall relieve Company of
responsibility for the performance of any accrued obligation under this Agreement, including without limitation Section 13.3 (Company’s Insurance) and Section 13.4 (Indemnification by Company). 

16.2.4 Any permitted assignee shall meet with representatives of UMB within [**] days of the closing of the transaction to
discuss the assignee’s plans for the future development, commercialization, and/or Sales of Licensed Products. If the assignee determines that it does not wish to continue the development, commercialization, and/or Sales of Licensed Products,
then the assignee shall immediately give notice terminating this Agreement under Section 10.3. 
 16.3 Assignment by UMB.
UMB may assign this Agreement to a successor-in-interest, but UMB may not otherwise assign or transfer this Agreement without the prior written consent of Company, which shall not be unreasonably withheld or delayed. 

  
 33 

 ARTICLE 17. MISCELLANEOUS 

17.1 Governing Law. This Agreement is made and construed in accordance with the laws of the State of Maryland without regard to choice
of law issues, except as set forth in Section 3.6.9. 
 17.2 Jurisdiction. Each Party consents to the jurisdiction and
venue of the courts of Baltimore City or Baltimore County, Maryland and the U.S. District Court for the District of Maryland in Baltimore, Maryland in any action or judicial proceeding brought to enforce, construe or interpret this Agreement. 

17.3 WAIVER OF TRIAL BY JURY. UMB AND COMPANY WAIVE THEIR RIGHTS TO TRIAL BY JURY IN ANY LITIGATION BETWEEN THEM RELATING TO THIS
AGREEMENT. 
 17.4 Entire Agreement. This Agreement, together with any Schedules specifically referenced and attached, embodies the
entire understanding between Company and UMB. Other than a Confidential Disclosure Agreement dated May 27, 2005, there are no contracts, understandings, conditions, warranties or representations, oral or written, express or implied, with
reference to the subject matter of this Agreement that are not merged in this Agreement. No oral statements or prior written material not specifically incorporated herein shall be of any force and effect. The Parties specifically acknowledge that in
entering into and executing this Agreement, the Parties relied solely upon the representations and agreements contained in this Agreement and no others. All prior representations or agreements, whether written or oral, not expressly incorporated
herein are superseded. 
 17.5 Severability. A ruling by any court that one or more of the provisions contained in this Agreement is
invalid, illegal, or unenforceable shall not in any respect affect any other provision of this Agreement. Thereafter, this Agreement shall be construed as if the invalid, illegal, or unenforceable provision had been amended to the extent necessary
to be enforceable within the jurisdiction of the court making the ruling. 
 17.6 Force Majeure. Neither Party is liable for failure
or delay in performing any of its obligations under this Agreement if the failure or delay is required in order to comply with any governmental regulation, request or order, or necessitated by other circumstances beyond the reasonable control of the
Party so failing or delaying, including but not limited to Acts of God, war (declared or undeclared), insurrection, terrorism, fire, flood, accident, labor strikes, work stoppage or slowdown (whether or not the labor event is within the reasonable
control of the Parties), or inability to obtain raw materials, supplies, power or equipment necessary to enable a Party to perform its obligations. Each Party shall: (a) promptly notify the other Party in writing of an event of force majeure,
the expected duration of the event and its anticipated effect on the ability of the Party to perform its obligations; and (b) make reasonable efforts to remedy the effects of the event of force majeure. 

  
 34 

 17.7 Amendments; Waivers. This Agreement, including Schedules, may not be amended, nor may
any right or remedy of either Party be waived, unless the amendment or waiver is in writing and signed by a duly authorized representative of each Party. 

17.8 Waivers; Cumulative Remedies. A failure or delay by a Party in exercising any of its rights or remedies under this Agreement does
not constitute a waiver of the rights or remedies, nor does any single or partial exercise of any right or remedy preclude any other or further exercise thereof or the exercise of any other right or remedy. The rights and remedies of the Parties
provided in this Agreement are cumulative and not exclusive of any rights or remedies provided by law. 
 17.9 Relationship Between the
Parties. UMB and Company are not (and nothing in this Agreement may be construed to constitute them as) partners, joint venturers, agents, representatives or employees of the other. Neither Party has any responsibility nor liability for the
actions of the other Party except as specifically provided in this Agreement. Neither Party has any right or authority to bind or obligate the other Party in any manner or make any representation or warranty on behalf of the other Party. 

17.10 Expenses. Except as otherwise specifically set forth herein, all costs and expenses incurred in connection with this Agreement
shall be paid by the Party which incurs the cost or expense, and the other Party has no liability for the cost or expense. 
 17.11 No
Third Party Beneficiaries. This Agreement is not intended to create, and does not create, enforceable legal rights as a third party beneficiary or through any other legal theory on the part of any UMB Personnel, or any other Person, except as
otherwise provided by Section 3.3 (Sublicenses) and Section 13.4 (Indemnification by Company). 
 17.12
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, and all of which shall together constitute one agreement. In proving this Agreement, it shall only be necessary to produce or
account for the counterpart signed by the Party against whom the proof is being presented. 
 17.13 Interpretation. Each Party to
this Agreement participated in the drafting of this Agreement. Each Party was represented by counsel, or had the opportunity to be represented by counsel. Therefore, no Party shall be deemed to be the “draftsman,” and ambiguities shall not
be construed against any particular Party. The section and subsection headings of this Agreement have been included for convenience only, are not part of this Agreement, and shall not be taken as an interpretation thereof. Whenever used herein, the
singular includes the plural and the plural includes the singular. The use of any gender, tense, or conjugation includes all genders, tenses, and conjugations. The words “including,” “inclusive,” or words of similar import shall
be construed to mean “including without limitation,” unless the context clearly indicates otherwise. References to “writing” or “written” include printing, typing, lithography, and other means of reproduction in a
visible form. References to agreements and other contractual instruments include all subsequent amendments thereto or changes therein entered into in accordance with their respective terms and not prohibited by this Agreement. 

  
 35 

 17.14 Further Assurances. The Parties shall execute and deliver and cause to be executed
and delivered further agreements, instruments and documents and shall take further actions as may reasonably be required or appropriate to carry out the terms and conditions of this Agreement. 

{SIGNATURES ON FOLLOWING PAGE} 

  
 36 

 SIGNATURE PAGE TO 

MASTER LICENSE AGREEMENT 

The Parties have caused this Agreement to be executed by their duly authorized representatives on the dates indicated below. 

 

											
	WITNESS:	 		  	UNIVERSITY OF MARYLAND, BALTIMORE.	  
					
	 /s/ illegible
	 		  	By:	  	 /s/ David J. Ramsay
	  	 	(SEAL	) 
		 		  		  	 David J. Ramsay, D.M., D. Phil.

President
	  			
					
		 		  	Date:	  	5/19/06	  			
			
	ATTEST:	 		  	TOKAI PHARMACEUTICALS, INC.	  
					
	 /s/ illegible
	 		  	By:	  	 /s/ Joseph A. Yanchik
	  	 	(SEAL	) 
		 		  		  	 Joseph A. Yanchik III
 Chief Executive
Officer
	  			
					
		 		  	Date:	  	May 15, 2006	  			

  
 37 

 SCHEDULE A 

PATENT RIGHTS 
 [**] 

  
 38 

 SCHEDULE B 

DUE DILIGENCE MILESTONES 
  

	1)	Within [**] months after the Effective Date: Submission to UMB of supporting data and a detailed timeline for in vivo validation and the completion of toxicology testing leading to an IND application to
the FDA or a similar application to a foreign equivalent of the FDA. 

  

	2)	Within [**] months after the Effective Date: Filing of an IND application with the FDA or a similar application to a foreign equivalent of the FDA for a Phase 1 Clinical Trial related to a Licensed Product.

  

	3)	Within [**] months after IND approval by the FDA or a foreign equivalent of the FDA: Commencement of the first Phase 1 Clinical Trial of a Licensed Product. 

 

	4)	Within [**] months after the completion of all Phase 1 Clinical Trials of a Licensed Product: Commencement of First Phase 2 Clinical Trial of a Licensed Product. 

 

	5)	Within [**] months after completion of all Phase 2 Clinical Trials of a Licensed Product: Commencement of First Phase 3 Clinical Trial of a Licensed Product. 

 

	6)	Within [**] months after completion of all Phase 3 Clinical Trials of a Licensed Product: Filing of an NDA or a BLA with the FDA for a Licensed Product or a similar application to a foreign equivalent of the FDA.

  

	7)	Within [**] months after approval by the FDA or foreign equivalent of the FDA: First Commercial Sale of a Licensed Product. 

  
 39 

 

 
 FIRST AMENDMENT TO LICENSE AGREEMENT 

This First Amendment (“First Amendment”) is effective as of the date of the last signature on the signature page
between the UNIVERSITY OF MARYLAND, BALTIMORE (“UMB”), a constituent institution of the University System of Maryland, a public corporation and an instrumentality of the State of Maryland, and TOKAI PHARMACEUTICALS, INC., a Delaware
corporation (“Company”). Company and UMB are referred to collectively as the “Parties” and each as a “Party.” 

BACKGROUND 

UMB and Company have entered into the Master License Agreement effective as of May 19, 2006 (“MLA”), under
which Company received an exclusive worldwide license to practice the Patent Rights. (Any capitalized term which is not otherwise defined in this First Amendment shall have the meaning set forth in the MLA.) 

A valuable invention generally known as “Novel Prodrugs of C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens:
Synthesis, In Vitro Biological Activities, Pharmacokinetics, and Antitumor Activity” (UMB ref: VN-2008-030) has been made by Dr. Vincent Njar, Dr. Angela Brodie, and Dr. Lalji Gediya, which constitutes an Improvement
pursuant to the MLA. 
 Company has duly exercised its Option to receive an exclusive license to the Improvement, pursuant to
Section 3.6 of the MLA. The Parties have negotiated in good faith to enter into this First Amendment to add the Improvement to the Patent Rights under the MLA, such that the invention will henceforth constitute a Licensed Improvement.

 The Parties agree to amend the MLA as set forth herein. 

NOW THEREFORE, the Parties agree as follows: 

1. Article 2 (Definitions) of the MLA is amended by deleting the definition of “TEC-COM.” Any reference in the MLA to
“TEC-COM” shall hereafter be amended to be a reference to “CVIP.” Article 2 is further amended by adding the following definitions: 

“CVIP”: The Commercial Ventures and Intellectual Property Group in UMB’s Office of Research and
Development, and any successor to its responsibilities. 
 “Initial Licensed Product”: Any product
(including without limitation any Combination Product) whose manufacture, use, Sale or import would infringe, or any process whose practice would infringe, the Initial Patent Rights. 

  

 “Initial Patent Rights”: The Patent Rights set forth in Part A
of Schedule A. 
 “Oral Prodrug Licensed Product”: An orally administered prodrug formulation
(including without limitation any Combination Product) whose manufacture, use, Sale or import would infringe, or any process whose practice would infringe, the Oral Prodrug Patent Rights. 

“Oral Prodrug Patent Rights”: The Patent Rights set forth in Part B of Schedule A. 

“Patent Expenses”: All fees, charges, expenses, and costs incurred before and after the Effective Date
in connection with the preparation, filing, prosecution, issuance, reissuance, reexamination, interference, and/or maintenance of patents or applications for patent or equivalent protection for the Patent Rights, including without limitation all
fees and charges of outside patent counsel. Patent Expenses shall be considered to be incurred when the fee, charge, expense, or cost is actually incurred (rather than when it is invoiced). For example, charges of outside patent counsel are
considered to be incurred as of the date on which the professional services are rendered. 
 “Patent
Rights”: (a) U.S. and foreign patents and patent applications listed in Schedule A, as it may be amended from time to time by mutual agreement of the Parties or to add Licensed Improvements pursuant to Section 3.6;
(b) all patents and patent applications related to clause (a), whether filed before or after the Effective Date, which claim priority under 35 U.S.C. §119 or the benefit of the filing date under 35 U.S.C. §120 or §371 (but only
to the extent of subject matter in a patent or patent application for which priority or benefit is claimed); (c) any substitution, divisional, continuation, and continuation-in-part (but only to the extent a Claim in the continuation-in-part is
directed to subject matter contained in a patent or patent application described in clause (a) or (b)); (d) any patent issuing from any patent or patent application described in clause (a), (b), or (c); (e) any reissue, renewal,
reexamination, or extension of any patent or patent application described in clause (a), (b), (c), or (d); and (f) any foreign counterpart or equivalent of any patent or patent application described in clause (a), (b),(c), (d), or (e).

 2. Schedule A (Patent Rights) of the MLA is hereby deleted in its entirety, and replaced with Schedule A attached hereto. 

3. Schedule B (Diligence Milestones) of the MLA is hereby deleted in its entirety, and replaced with Schedule B attached
hereto. 
 4. Section 4.1 (R&D Plan and Business Plan) is hereby amended by adding the following: 

  
 2 

 4.1.3 Company shall promptly notify UMB of any substantial change in the R&D
Plan or Business Plan if such change will materially alter or affect the timely achievement of any milestone set forth on Schedule B. Any amendment of the R&D Plan or Business Plan that will materially alter or affect the timely
achievement of any milestone shall require the consent and approval of UMB, which shall not be unreasonably withheld, delayed or conditioned. The Parties shall negotiate in good faith and amend any provision of this Agreement to the extent
reasonably necessary to conform to any approved modification of the R&D Plan or Business Plan, including without limitation the milestones set forth on Schedule B and the milestone payments set forth in Section 5.3. 

5. Section 5.3 (Milestone Payments) is hereby deleted in its entirety, and replaced with the following: 

5.3 Milestone Payments. Company shall pay to UMB the following milestone payments: 

 

					
	On submission of each IND for a Licensed Product to the U.S. FDA:	  	U.S. $50,000.00	  	Within [**] days following submission
			
	On approval of each NDA or BLA for a Licensed Product by the U.S. FDA:	  	U.S. $100,000.00	  	Within [**] days following receipt of approval
			
	Upon issuance of the first patent citing U.S. Provisional Patent Application No. 61/039,133 as priority	  	U.S. $40,000.00	  	Within [**] days following issuance

 6. Section 10.2.2 (Diligence Default) is hereby deleted in its entirety, and replaced with the
following: 
 10.2.2 Diligence Default. In the event of any default or material breach of Section 4.3 (Due
Diligence Milestones) due to Company failing to timely achieve a milestone set forth on Schedule B, as such milestones may from time to time be amended as contemplated by Section 4.1.3 hereof and then in effect, and the failure is
not cured within [**] days of written notice thereof, UMB may terminate the license granted under this Agreement to the category of Patent Rights to which such milestone relates as shown on Schedule B (i.e. Initial Patent Rights or Oral
Prodrug Patent Rights). However, if that failure cannot be cured by the exercise of due diligence within [**] days of written notice, then the time for cure shall be extended for the time reasonably necessary to effect the cure (the extension not to
exceed an additional [**] days), provided that Company promptly commences to cure within said period and at all times thereafter proceeds diligently to cure the failure. The termination of the license granted hereunder for any category of Patent
Rights to which such milestone relates as 

  
 3 

 
shown on Schedule B shall not affect the license granted hereunder for any other Patent Rights related to the milestones shown on such Schedule B. The withholding by a regulatory
agency of marketing or other approval in spite of Company’s Commercially Reasonable Efforts to obtain the approval shall not constitute a default or material breach of Section 4.3 (Due Diligence Milestones). 

7. Section 15.1 (Notices) of the MLA is hereby amended by deleting the address for UMB, and replacing it with the following: 

If to UMB: 

Commercial Ventures & Intellectual Property 

Office of Research and Development 

University of Maryland, Baltimore 

620 West Lexington Street, 4th Floor 

Baltimore, Maryland 21201 

Attn: Executive Director 

Copy to: 

University Counsel 

University of Maryland, Baltimore 

220 Arch Street, Room 03-111 

Baltimore, Maryland 21201 

8. In consideration of the license to the Oral Prodrug Patent Rights granted under this First Amendment, Company agrees to pay a one-time,
non-refundable license fee of Ten Thousand Dollars ($10,000) to UMB on or before execution of this First Amendment. 
 9. Company shall be
responsible for payment of all Patent Expenses regarding the Oral Prodrug Patent Rights incurred before the effective date of this First Amendment (to the extent not reimbursed to UMB by a Third Party) and during the Term, in accordance with
Section 6.3 of the MLA. 
 10. Except as specifically modified in this First Amendment, all terms and conditions of the MLA
(including without limitation the royalty rate and other payment obligations of Company) shall remain in full force and effect. 

{Signatures on following page} 

  
 4 

 IN WITNESS WHEREOF, each Party has caused this First Amendment to be executed under seal by its
duly authorized representative. 
  

									
	WITNESS:	  		  	UNIVERSITY OF MARYLAND, BALTIMORE
					
	 /s/ illegible
	  		  	By:	  	 /s/ David J. Ramsay
	  	(SEAL)
		  		  		  	 David J. Ramsay; D.M., D. Phil.

President
	  	
					
		  		  	Date:	  	March 3, 2009	  	
			
	WITNESS/ATTEST:	  		  	TOKAI PHARMACEUTICALS, INC.
					
		  		  	By:	  	 /s/ Scott Chappel
	  	
		  		  		  	(SEAL)	  	
					
	 /s/ illegible
	  		  	Title:	  	CSO	  	
					
		  		  	Date:	  	2/19/09	  	

  
 5 

 SCHEDULE A 

PATENT RIGHTS 
 Confidential Materials
omitted and filed separately with the Securities and Exchange Commission. A total of three pages were omitted. [**] 

  

 SCHEDULE B 

DUE DILIGENCE MILESTONES 
 INITIAL LICENSED PRODUCTS

  

	1)	Within [**] months after the Effective Date: Submission to UMB of supporting data and a detailed timeline for in vivo validation and the completion of toxicology testing leading to an IND application to the FDA
or a similar application to a foreign equivalent of the FDA related to an Initial Licensed Product. 

  

	2)	Within [**] months after the Effective Date: Filing of an IND application with the FDA or a similar application to a foreign equivalent of the FDA for a Phase 1 Clinical Trial related to an Initial Licensed
Product. 

  

	3)	Within [**] months after IND approval by the FDA or a foreign equivalent of the FDA: Commencement of the first Phase 1 Clinical Trial of an Initial Licensed Product. 

 

	4)	Within [**] months after the completion of all Phase 1 Clinical Trials of an Initial Licensed Product: Commencement of First Phase 2 Clinical Trial of an Initial Licensed Product. 

 

	5)	Within [**] months after completion of all Phase 2 Clinical Trials of an Initial Licensed Product: Commencement of First Phase 3 Clinical Trial of an Initial Licensed Product. 

 

	6)	Within [**] months after completion of all Phase 3 Clinical Trials of an Initial Licensed Product: Filing of an NDA or a BLA with the FDA for an Initial Licensed Product or a similar application to a foreign
equivalent of the FDA. 

  

	7)	Within [**] months after approval by the FDA or foreign equivalent of the FDA: First Commercial Sale of an Initial Licensed Product. 

ORAL PRODRUG LICENSED PRODUCTS 
  

	1)	Within [**] months following the execution of this First Amendment: Submission to UMB of (a) an R&D Plan reasonably acceptable to UMB, showing the amount of money and time budgeted and planned for
technical development of the Oral Prodrug Patent Rights, and (b) a Business Plan reasonably acceptable to UMB, showing the proposed commercialization scheme for Oral Prodrug Licensed Products. 

 

	2)	Within [**] months after the submission of the R&D Plan and Business Plan: Submission to UMB of supporting data and a detailed timeline for in vivo validation and the completion of toxicology testing leading
to an IND application to the FDA or a similar application to a foreign equivalent of the FDA related to an Oral Prodrug Licensed Product. 

  
 2 

	3)	Within [**] months after the submission of the R&D Plan and Business Plan: Filing of an IND application with the FDA or a similar application to a foreign equivalent of the FDA for a Phase 1 Clinical Trial
related to an Oral Prodrug Licensed Product. 

  

	4)	Within [**] months after IND approval by the FDA or a foreign equivalent of the FDA: Commencement of the first Phase 1 Clinical Trial of an Oral Prodrug Licensed Product. 

 

	5)	Within [**] months after the completion of all Phase 1 Clinical Trials of an Oral Prodrug Licensed Product: Commencement of First Phase 2 Clinical Trial of an Oral Prodrug Licensed Product. 

 

	6)	Within [**] months after completion of all Phase 2 Clinical Trials of an Oral Prodrug Licensed Product: Commencement of First Phase 3 Clinical Trial of an Oral Prodrug Licensed Product. 

 

	7)	Within [**] months after completion of all Phase 3 Clinical Trials of an Oral Prodrug Licensed Product: Filing of an NDA or a BLA with the FDA for an Oral Prodrug Licensed Product or a similar application to a
foreign equivalent of the FDA. 

  

	8)	Within [**] months after approval by the FDA or foreign equivalent of the FDA: First Commercial Sale of an Oral Prodrug Licensed Product. 

  
 3 

 

 
 SECOND AMENDMENT TO LICENSE AGREEMENT 

This Second Amendment to License Agreement (“Second Amendment”) is effective as of the date of the last signature on
the signature page between the UNIVERSITY OF MARYLAND, BALTIMORE (“UMB”), a constituent institution of the University System of Maryland, a public corporation and an instrumentality of the State of Maryland, and TOKAI
PHARMACEUTICALS, INC., a Delaware corporation (“Company”). Company and UMB are referred to collectively as the “Parties” and each as a “Party.” 

BACKGROUND 

UMB and Company entered into a Master License Agreement, effective as of May 9, 2006 (“MLA”) and first
amended March 3, 2009, under which Company received an exclusive worldwide license to practice the Patent Rights. (Any capitalized term which is not otherwise defined in this Second Amendment shall have the meaning set forth in the MLA.) 

A valuable invention generally known as “CYP17 Inhibitor VN/124-1 Inhibits Growth of Androgen Independent Prostate Cancer
Cells via Induction of the Endoplasmic Reticulum Stress Response” (UMB ref: VN-2008-067) has been made by Dr. Vincent Njar, Dr. Angela Brodie, and Dr. Robert Bruno, which x constitutes an Improvement pursuant to the
MLA. 
 Company has duly exercised its Option to receive a license to the Improvement, pursuant to Section 3.6 of
the MLA. The Parties have negotiated in good faith to enter into this Second Amendment to add the Improvement to the Patent Rights under the MLA, such that the invention will henceforth constitute a Licensed Improvement on the terms and conditions
set forth in this Second Amendment. 
 Since entering into the MLA, UMB has been solely responsible for preparing, filing,
prosecuting, and maintaining the Patent Rights. Company has requested the right to assume responsibility for patent prosecution upon execution of this Second Amendment. 

The Parties agree to amend the MLA as set forth herein. 

NOW THEREFORE, the Parties agree as follows: 

1. Article 2 (Definitions) of the MLA is hereby amended by deleting the definition of “CVIP.” Any reference in the
MLA to “CVIP” shall hereafter be amended to be a reference to “OTT.” Article 2 (Definitions) of the MLA is further amended by adding the following definitions: 

 “ER Stress Response Licensed Product”: Any product (including
without limitation any Combination Product) whose manufacture, use, Sale or import would infringe, or any process whose practice would infringe, the ER Stress Response Patent Rights. 

“ER Stress Response Patent Rights”: The Patent Rights set forth in Part C of Schedule A. 

“OTT”: The Office of Technology Transfer in UMB’s Office of Research and Development, and any successor
to its responsibilities. 
 2. Schedule A (Patent Rights) of the MLA is hereby amended by adding the following: 

[**] 
 3. Section 6.1 of the MLA is hereby
deleted in its entirety, and replaced with the following: 
 6.1 Patent Prosecution Responsibility and General Issues.

 6.1.1 On and after the date of execution of this Second Amendment, Company shall assume sole responsibility for preparing,
filing, prosecuting, and maintaining the Patent Rights (including without limitation defense of the Patent Rights in an interference proceeding). 

6.1.2 UMB and Company shall not be liable for any loss, in whole or in part, of a patent term extension granted by the U.S.
Patent and Trademark Office on a patent issuing under Patent Rights, even if such loss resulted from the acts or omissions of UMB, UMB Personnel working under their direction or supervision, Company, Company Personnel, or Company’s patent
counsel. 
 6.1.3 Following execution of this Second Amendment, the Patent Rights will be prepared, prosecuted, filed, and
maintained by Company’s current independent patent counsel. However, Company shall change patent counsel if reasonably requested by UMB. Company’s choice of outside patent counsel is subject to UMB’s prior approval, which approval
must not be unreasonably withheld. Outside patent counsel will be ultimately responsible to Company. Company authorizes UMB to communicate directly with Company’s outside patent counsel. 

6.1.4 Company shall (and shall instruct outside patent counsel to) (i) advise UMB promptly as to all material developments
with respect to the Patent Rights, and (ii) promptly provide copies of all communications received and filed in connection with prosecution of Patent Rights. 

  
 2 

 6.1.5 Company shall promptly notify UMB, and Company shall instruct outside
patent counsel to promptly notify UMB, before taking any substantive actions in prosecuting the Claims. UMB may provide comments and suggestions with respect to any substantive actions to be taken by Company, and comment on the type and scope of
Claims and the nature of supporting disclosures. Company shall reasonably consider all comments and suggestions and shall take all prosecution actions reasonably recommended by UMB. 

6.1.6 Company shall not do any of the following with respect to the Patent Rights, except upon prior approval of UMB:
materially modify or limit the scope of patent coverage; modify the identification of inventors; or finally abandon any patent or patent application. 

6.1.7 If UMB and Company do not agree on actions relating to the scope of patent coverage for any of the Patent Rights
reasonably recommended to Company by UMB under Section 6.1.5, then UMB may terminate immediately Company’s right to prosecute the patent application(s) involved, and in such case UMB may continue prosecution using its own
independent counsel. Before UMB terminates the Company’s right to prosecute the patent application(s) involved, UMB shall reasonably consider any comments provided by Company regarding prosecution of the Claims. 

6.1.8 All information exchanged between the parties or between Company’s outside patent counsel and UMB regarding
preparation, filing, prosecution, or maintenance of the Patent Rights shall be deemed Confidential Information. In addition, the parties acknowledge and agree that, with regard to such preparation, filing, prosecution, and maintenance of the Patent
Rights, the interests of the parties as licensor and licensee are to obtain the strongest and broadest patent protection possible. The parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of,
any legal privilege concerning the Patent Rights, including without limitation privilege under the common interest doctrine and similar or related doctrines. “ 

4. Section 6.2 of the MLA is hereby deleted in its entirety, and replaced with the following: 

6.2 Foreign Patent Prosecution. 

6.2.1 If Company gives at least [**] days prior written notice to UMB, Company may elect to discontinue support for Patent
Expenses with respect to any particular Patent Right, but UMB’s written consent shall be required prior to discontinuing support for Patent Expenses in the United States, Japan, Australia, Canada, United Kingdom, France, Germany or Spain.
Company shall be responsible for reasonable Patent Expenses incurred in that [**] day period with respect to the county or countries where the Company is ceasing support. From and after UMB’s receipt of Company’s notice, Company’s
rights in Patent Rights will terminate with respect to the country or countries where 

  
 3 

 
Company is ceasing support, and Company shall execute such documents as reasonably may be requested by UMB to confirm termination of Company’s rights. 

6.2.2 UMB may elect to file and prosecute patent applications, solely at its own expense, in foreign countries where Company
has declined or failed to pay Patent Expenses for such patent applications. If UMB so elects, in those countries, Company will have no input into patenting decisions, no license rights with respect to those Patent Rights, and no Option rights with
respect to related Improvements. 
 5. Section 6.3 of the MLA is hereby deleted in its entirety, and replaced with the following: 

6.3 Patent Expenses. 

6.3.1 Company shall be solely responsible for all Patent Expenses. Company shall reimburse UMB for Patent Expenses which were
incurred prior to the execution of this Second Amendment, resulted from instructions given by Company prior to that date, or otherwise were incurred by UMB as agreed between the Parties or pursuant to the terms of this Agreement. Company shall pay
each undisputed invoice for Patent Expenses in full within [**] days after the date of invoice. 
 6.3.2 If this Agreement is
terminated for any reason other than expiration, Company will have no obligation to pay Patent Expenses related to Patent Rights incurred by UMB for patent filing and prosecution activities occurring more than [**] days after Company’s notice
of termination, and no obligation to pursue prosecution of patent applications related to Patent Rights and pay related Patent Expenses for more than [**] days following notice of termination. UMB will act in good faith to minimize the Patent
Expenses incurred between receipt of notice of termination and the end of the [**] day period. 
 6. In consideration of the license granted
under this Second Amendment, Company agrees to pay a one-time, non-refundable license fee of Ten Thousand Dollars ($10,000) to UMB on or before execution of this Second Amendment. 

7. Except as specifically modified in this Second Amendment, all terms and conditions of the MLA (including without limitation the royalty
rate and other payment obligations of Company) shall remain in full force and effect. 
 IN WITNESS WHEREOF, each Party has caused this
Second Amendment to be executed under seal by its duly authorized representative. 
  

									
	WITNESS:	 		 	UNIVERSITY OF MARYLAND, BALTIMORE	 	

  
 4 

									
					
	 /s/ Dorothy C. [illegible]
	 		 	By:	 	/s/ Jay A. Perman	 	(SEAL)
		 		 		 	Jay A. Perman, M.D.	 	
		 		 	Title:	 	President	 	
		 		 	Date:	 	4/10/12	 	

  

									
	ATTEST:	 		 	TOKAI PHARMACEUTICALS, INC.	 	
					
		 		 	By:	 	/s/ Martin D. Williams	 	(SEAL)
	 /s/ Holly [illegible]
	 		 		 		 	
		 		 	Name:	 	Martin D. Williams	 	
		 		 	Title:	 	CEO	 	
		 		 	Date:	 	April 9, 2012	 	

  
 5 

 THIRD AMENDMENT TO LICENSE AGREEMENT 

This Third Amendment to License Agreement (“Third Amendment”) is effective as of the date of the last signature on the
signature page hereto and is between the UNIVERSITY OF MARYLAND, BALTIMORE (“UMB”), a constituent institution of the University System of Maryland, a public corporation and an instrumentality of the State of Maryland, and TOKAI
PHARMACEUTICALS, INC., a Delaware corporation (“Company”). Company and UMB are referred to collectively as the “Parties” and each as a “Party.” 

BACKGROUND 

UMB and Company entered into a Master License Agreement, effective as of May 9, 2006, as amended
(“MLA”), under which Company received an exclusive worldwide license to practice the Patent Rights. (Any capitalized term which is not otherwise defined in this Third Amendment shall have the meaning set forth in the MLA.) 

A valuable invention generally known as “Androgen Receptor Down-regulating Agents for the Treatment of All Forms of
Prostate Cancer” (UMB ref: VN-2013-061) (the “ARDA Invention”) has been made by Vincent Njar, Puranik Purushottamachar, Lalji K. Gediya, Abhijit M. Godbole (all employees of UMB and formerly of Thomas Jefferson
University), Andrew K. Kwegyir-Afful (an employee of UMB), and Tadas S. Vasaitis (an employee of University of Maryland, Eastern Shore), which constitutes an Improvement pursuant to the MLA. 

UMB, Thomas Jefferson University, and the University of Maryland, Eastern Shore each own an undivided joint interest in the
ARDA Invention. UMB has been granted the exclusive right to negotiate, execute, and administer any license agreement related to the ARDA Invention on behalf of the co-owning institutions, pursuant to an Inter-Institutional Agreement dated as of
June 30, 2013 (the “IIA”), a fully-executed copy of which is attached to this Third Amendment as Exhibit A. 

Company has duly exercised its Option to receive a license to the Improvement, pursuant to Section 3.6 of the MLA. The
Parties have negotiated in good faith to enter into this Third Amendment to add exclusive rights of all co-owners of the Improvement to the Patent Rights under the MLA, such that the ARDA Invention will henceforth constitute a Licensed Improvement
on the terms and conditions set forth in this Third Amendment. 
 Company desires to retain its license rights with respect
to the Oral Prodrug Patent Rights. However, Company has requested, and UMB has agreed, to delete the requirement of achieving diligence milestones with respect to Oral Prodrug Licensed Products, because development of an oral prodrug will likely not
be required for clinical development and commercialization of a Licensed Product. 

 The Parties agree to amend the MLA as set forth herein. 

NOW THEREFORE, the Parties agree as follows: 

1. Article 2 (Definitions) of the MLA is hereby amended by adding the following definitions: 

“ARDA Licensed Product”: Any product (including without limitation any Combination Product) whose manufacture,
use. Sale or import would infringe, or any process whose practice would infringe, the ARDA Patent Rights. 
 “ARDA
Patent Rights”: The Patent Rights set forth in Part D of Schedule A. 
 2. A new Section 4.4 is added to the MLA
as follows: 
 4.4 ARDA Licensed Products. Notwithstanding anything herein to the contrary: 

4.4.1 Within [**] years from the effective date of this Third Amendment, Company shall submit to UMB (a) an R&D Plan
reasonably acceptable to UMB, showing the amount of money and time budgeted and planned for technical development of the ARDA Patent Rights, and (b) a Business Plan reasonably acceptable to UMB, showing the proposed commercialization scheme for
ARDA Licensed Products. Alternatively, Company may elect to terminate the license granted hereunder with respect to the ARDA Patent Rights. 

4.4.2 If Company submits the R&D Plan and Business Plan contemplated in Section 4.4.1, upon approval by UMB,
the Parties shall negotiate in good faith appropriate amendments to Schedule B (Diligence Milestones) to add diligence milestones for development and commercialization of ARDA Licensed Products. 

4.4.3 If Company submits the R&D Plan and Business Plan contemplated in Section 4.4.1, thereafter Company
shall provide prompt written notice to UMB if and when: (a) Company elects to discontinue efforts under the R&D Plan and the Business Plan with respect to ARDA Patent Rights and ARDA Licensed Products: or (b) Company determines that it
is not technically or commercially feasible to develop and/or commercialize ARDA Licensed Products. 
 4.4.4 Upon receipt of
the notice contemplated in Section 4.4.3, UMB may, within [**] days after receipt, either: (a) convert the license granted hereunder with respect to ARDA Patent Rights to a nonexclusive license; or (b) terminate the license
granted hereunder with respect to ARDA Patent Rights; provided, however, if the notice contemplated in Section 4.4.3 states that the Company has determined that it is not technically or commercially feasible to develop
and/or commercialize ARDA Licensed Products, then UMB may only 

  
 2 

 
convert the license granted hereunder with respect to ARDA Patent Rights to a non-exclusive license. 

3. Schedule A (Patent Rights) of the MLA is hereby amended by adding the following: 

[**] 
 4. Schedule B (Diligence Milestones) of
the MLA is hereby amended by deleting in its entirety the section related to the Oral Prodrug Licensed Products. 
 5. UMB hereby represents
that, as of the effective date of this Third Amendment, the IIA has been executed by duly authorized representatives of each of the parties thereto and that the IIA is in full force and effect in accordance with its terms. 

6. In consideration of the license granted under this Third Amendment, Company agrees to pay a one-time, non-refundable license fee of Ten
Thousand Dollars ($10,000) to UMB within [**] business days of the execution of this Third Amendment by both parties. 
 7. Except as
specifically modified in this Third Amendment, all terms and conditions of the MLA (including without limitation the royalty rate and other payment obligations of Company) shall remain in full force and effect. 

IN WITNESS WHEREOF, each Party has caused this Third Amendment to be executed under seal by its duly authorized representative. 

 

									
	WITNESS:	 		 	UNIVERSITY OF MARYLAND, BALTIMORE	 	
					
		 		 	By:	 	/s/ Jay A. Perman	 	(SEAL)
	 /s/ Dorothy C. [illegible]
	 		 		 	Jay A. Perman, M.D.	 	
		 		 	Title:	 	President	 	
		 		 	Date:	 	10/28/13	 	

  

									
	WITNESS/ATTEST:	 		 	TOKAI PHARMACEUTICALS, INC.	 	
					
		 		 	By:	 	/s/ Jodie Morrison	 	(SEAL)
		 		 	Name:	 	Jodie Morrison	 	
		 		 	Title:	 	Chief Executive Officer	 	
		 		 	Date:	 	10/23/13	 	

  
 3 

  

INTER-INSTITUTIONAL AGREEMENT 

BETWEEN 
 UNIVERSITY OF
MARYLAND, BALTIMORE 
 AND 

UNIVERSITY OF MARYLAND, EASTERN SHORE 

AND 
 THOMAS JEFFERSON
UNIVERSITY 
  
  

 

			
	UMB Docket No.:	  	TJU Docket No:
		
	VN-2013-061	  	NJA_VIN.007

 INTER-INSTITUTIONAL AGREEMENT 

This Inter-Institutional Agreement (“Agreement”) is effective as June 30, 2013 (“Effective
Date”) by and between the UNIVERSITY OF MARYLAND, BALTIMORE (“UMB”); the UNIVERSITY OF MARYLAND, EASTERN SHORE (“UMES”) (by the University of Maryland, College Park, Office of Technology Commercialization);
and THOMAS JEFFERSON UNIVERSITY (“TJU”), a Pennsylvania non-profit organization. UMB and UMES are both constituent institutions of the University System of Maryland (“USM”), which is a public corporation and an
instrumentality of the State of Maryland. 
 BACKGROUND 

B-l. A valuable invention generally known as “Androgen Receptor Down-regulating Agents for the Treatment of All Forms
of Prostate Cancer” (the “Joint Invention”) has been made by Vincent Njar, Puranik Purushottamachar, Lalji K. Gediya, Abhijit M. Godbole (all employees of UMB and formerly of TJU), Andrew K. Kwegyir-Afful (an
employee of UMB), and Tadas S. Vasaitis (an employee of UMES). 
 B-2. UMB, TJU, and UMES have separate agreements
with their respective inventors or have intellectual property policies pursuant to which (a) their respective inventors assigned (or are required to assign) all right, title, and interest in the Joint Invention to their institution, and
(b) their respective inventors agreed (or are required) to cooperate with and assist their respective institution in preparing, filing, prosecuting, and maintaining patent applications and patents relating to the Joint Invention. 

B-3. The Joint Invention was made with government support under National Institutes of Health Grants CA117991 and CA129379.

 B-4. UMB and Tokai Pharmaceuticals, Inc. (“Tokai”) have entered into a Master License Agreement,
effective as of May 9, 2006, as amended (the “Tokai MLA”), pursuant to which Tokai was granted an exclusive license to six (6) other technologies which are solely owned by UMB (the “UMB Technologies”).

 B-5. The Tokai MLA granted to Tokai an option to license any “Improvements” to the UMB Technologies. The Joint
Invention constitutes such an “Improvement,” and Tokai has exercised its option to license the Joint Invention. UMB has negotiated with Tokai an amendment to the Tokai MLA for such license. 

ARTICLE 1. DEFINITIONS 
 In this
Agreement, the following terms have the meanings set forth in this Article. 
 “Administrative Fee”: [REDACTED] 

 “Confidential Information”: Information (including without limitation
documents, notes, drawings, models, designs, data, results, memoranda, tapes, records, hardware, software, formulae and algorithms, in hard copy form or in electronic form) which is not generally available to the public and which is disclosed by a
party to the other party in connection with this Agreement, including without limitation information that: (a) is related to and results from or arises out of use of the Joint Invention or the Patent Rights, or (b) is reasonably necessary
for the practice of the Patent Rights or for the development or commercialization of Licensed Products. 
 “Federal IP
Policy”: U.S. law and regulations applicable to intellectual property funded in whole or in part by the U.S. Government pursuant to which the U.S. Government retains certain rights, including without limitation 35 U.S.C. §200
et seq., 15 U.S.C. §3710a, and 37 C.F.R. Part 401. 
 “Gross Income”: All cash and
non-cash consideration actually received from or in connection with the Tokai MLA that is allocable to the Joint Invention. If any payment under the Tokai MLA is not separately allocated to the Joint Invention, it is agreed that such payment will be
allocated [REDACTED] Invention. 
 “Infringe,” “infringement,” or any correlative term: Any
infringement (whether direct, indirect, contributory or otherwise) of the intellectual property rights of UMB, TJU, or UMES (including without limitation under the doctrines of claim construction or differentiation, literal overlap or equivalents);
or any misuse, misappropriation, theft, or breach of confidence related to the Joint Invention and/or the Patent Rights. 

“Inventor”: Each of the personnel of UMB, TJU, and UMES who invented the Joint Invention, as identified in Section
B-l. 
 “Licensed Product”: Any product, service, or process, the making, use, offer for sale, sale,
importation, or providing of which uses the Joint Invention or any technology disclosed in the Patent Rights. 
 “Net
Revenues”: Gross Income less (a) unreimbursed Patent Expenses, and (b) the Administrative Fee. 

“OTT”: The Office of Technology Transfer group in UMB’s Office of Research and Development, and any successor to
its responsibilities. 
 “Patent Expenses”: All fees, charges, expenses, and costs incurred before and after
the Effective Date with respect to the Joint Invention in connection with the preparation, filing, prosecution, issuance, reissuance, reexamination, interference, enforcement, and/or maintenance of patents or patent applications relating to the
Patent Rights, including without limitation all fees and charges of outside patent counsel or patent agent. Patent Expenses shall be considered to be incurred when the fee, charge, expense, or cost is actually incurred (rather than when it is
invoiced). For example, charges of outside patent counsel are considered to be incurred as of the date on which the professional services are rendered. 

  
 2 

 “Patent Rights”: (a) U.S. and foreign patents and patent
applications listed in Schedule A, as it may be amended from time to time by mutual agreement of the parties; (b) all patents and patent applications related to clause (a), whether filed before or after the Effective Date, which claim priority
under 35 U.S.C. §119 or the benefit of the filing date under 35 U.S.C. §120 or §371 (but only to the extent of subject matter in a patent or patent application for which priority or benefit is claimed); (c) any substitution,
divisional, continuation, and continuation-in-part (but only to the extent a claim in the continuation-in-part is directed to subject matter contained in a patent or patent application described in clause (a) or (b)); (d) any patent
issuing from any patent or patent application described in clause (a), (b), or (c); (e) any reissue, renewal, reexamination, or extension of any patent or patent application described in clause (a), (b), (c), or (d); and (f) any foreign
counterpart or equivalent of any patent or patent application described in clause (a), (b), (c), (d), or (e). 
 ARTICLE 2. OWNERSHIP;
RESERVED RIGHTS; CONFIDENTIAL INFORMATION 
 2.1 Ownership. 

2.1.1 Subject to certain rights retained by the U.S. Government in inventions resulting from federally supported work pursuant
to Federal IP Policy, UMB, TJU, and UMES each own an undivided joint interest in and to the Joint Invention and Patent Rights. 

2.1.2 During the Term: (a) TJU and UMES shall forbear granting to any third party (other than to UMB) any right, title, or
interest in, to or under the Joint Invention and Patent Rights, and (b) TJU and UMES grant to UMB the sole responsibility for administering and commercializing the Joint Invention and Patent Rights. 

2.2 Reservation of Rights. The following rights are specifically reserved with respect to the Joint Invention and the Patent Rights by
each of the parties: 
 2.2.1 To use the Joint Invention, practice under the Patent Rights, and to make and use Licensed
Products on a non-exclusive, royalty-free basis for research, scholarly use, teaching, education, patient care incidental to the foregoing, and other similar uses, including without limitation sponsored research and collaborations
(“Non-Commercial Uses”); 
 2.2.2 To license government agencies, universities or other educational
institutions, organizations of the type described in §501(c)(3) of the Internal Revenue Code, scientific or educational organizations qualified under a state nonprofit organization statute (or foreign equivalents of the foregoing)
(“Non-Commercial Organizations”) use the Joint Invention, practice under the Patent Rights, and to make and use Licensed Products on a non-exclusive, royalty-free basis solely for Non-Commercial Uses; and to provide material and
information (excluding Company’s Confidential Information) to Non-Commercial Organizations solely for Non-Commercial Uses; and 

2.2.3 To disseminate and publish scientific findings from research related to the Joint Invention, Patent Rights, and/or
Licensed Products, and to permit its respective personnel to do the same, subject to Schedule B (Confidentiality). 

  
 3 

 2.3 Reporting. Each party is responsible for making all reports required
to be made by it by the Federal Government or other sponsors research related to the Joint Invention. 
 2.4
Confidentiality. The parties agree to abide by the terms and conditions of Schedule B regarding Confidential Information. 

ARTICLE 3. PATENT PROSECUTION 

3.1 Prosecution. 

3.1.1 In the event that the Joint Invention is licensed to Tokai pursuant to the Tokai MLA and the Tokai MLA is in effect, UMB
shall have the sole discretion to make decisions with respect to patent applications and patent preparation, filing, prosecution, and maintenance, subject to the conditions set forth in this Agreement. UMB may retain legal counsel of its choosing.

 3.1.2 It is understood that Tokai has been granted the right to control patent prosecution, pursuant to the terms of the
Tokai MLA. UMB will promptly advise UMES and TJU if it receives information from Tokai or its outside patent counsel of material developments with respect to the Patent Rights regarding the Joint Invention. If UMB receives any communications in
connection with prosecution of Patent Rights regarding the Joint Invention, UMB will promptly provide copies of the same to UMES and TJU. 

3.1.3 If UMB has an opportunity to provide comments and suggestions with respect to any substantive actions to be taken by
Tokai with respect to the Patent Rights regarding the Joint Invention, or to comment on the type and scope of claims and the nature of supporting disclosures, it will solicit comments and suggestions from TJU and UMES. UMB will forward any such
comments and suggestions which UMB receives from TJU and/or UMES. 
 3.1.4(a) In the event that the Tokai MLA is no longer in
effect or that the Joint Invention is no longer licensed to Tokai pursuant to the Tokai MLA, UMB shall have the sole discretion to make decisions with respect to patent applications and patent preparation, filing, prosecution, and maintenance,
subject to the conditions set forth in this Section 3.1.4. 
 (b) If Section 3.1.4(a) is applicable,
UMB shall consult with, incorporate reasonable input from, and keep UMES and TJU informed as to the preparation, filing, prosecution, and maintenance of all applicable patent applications and patents. UMB shall send UMES and TJU copies of formal
correspondence with the U.S. Patent and Trademark Office and with any foreign patent office concerning the preparation, filing, prosecution, and maintenance of all applicable patent applications and patents. 

(c) If UMB desires to discontinue prosecution of any patent application or maintenance of any patent within any country, it
shall first give written notice of its intent to UMES and TJU at least sixty (60) days prior to the next applicable deadline. UMES and/or TJU may assume responsibility for paying Patent Expenses in that country by providing written notice to
UMB at least thirty (30) days prior to the next applicable deadline. In that event, UMES and/or TJU, as the case may be, shall thereafter be responsible at its sole expense 

  
 4 

 
in that country for patent prosecution or maintenance of those Patent Rights. Any party who is not responsible for paying Patent Expenses in that country thereby relinquishes rights to revenues
resulting from those Patent Rights within such country. 
 3.2 Patent Expenses. 

3.2.1 Under the Tokai MLA, Tokai is responsible to pay Patent Expenses. If any Patent Expenses are not otherwise reimbursed or
reimbursable under the Tokai MLA, each party shall be responsible for a portion of Patent Expenses in proportion to the number of Inventors of the Joint Invention from each party’s institution, as follows: [REDACTED] 

3.2.2 UMB may advance Patent Expenses, and may invoice TJU and UMES for its share. TJU and UMES shall reimburse UMB within
thirty (30) days of receipt of invoice therefor. UMB shall maintain adequate records showing all Patent Expenses incurred. These records shall be made available to TJU and UMES for inspection on reasonable notice. 

3.3 Consultation and Notice. UMB shall consult with and keep TJU and UMES informed as to the preparation, filing,
prosecution, and maintenance of all applicable patent applications and patents. UMB shall send TJU and UMES copies of formal correspondence with the U.S. Patent and Trademark Office and with any foreign patent office concerning the preparation,
filing, prosecution, and maintenance of all applicable patent applications and patents. 
 ARTICLE 4. LICENSING OF THE JOINT INVENTION 

4.1 Licensing. 

4.1.1 UMB shall have the sole right, on behalf of the parties, to grant a license to the Joint Invention to Tokai, as an
amendment to the Tokai MLA, on terms and conditions to be negotiated by UMB. 
 4.1.2 UMB shall be responsible for assuring
compliance by Tokai in accordance with the terms of the Tokai MLA, for otherwise enforcing the Tokai MLA, and for protecting the rights of the parties pursuant to and in accordance with this Agreement. UMB shall consult with and keep TJU and UMES
reasonably promptly informed with respect to all material matters during administration of the Tokai MLA as it relates to the Joint Invention. 

ARTICLE 5. LICENSING REVENUE 

5.1 UMB shall use reasonable efforts to collect all material amounts due under the Tokai MLA with respect to the Joint
Invention. UMB shall calculate: (a) the amount of Gross Income; (b) the amount of each party’s unreimbursed Patent Expenses, (c) the Administrative Fee, and (d) Net Revenues. UMB shall provide a written report of its
calculations to TJU and UMES periodically, but no less often than annually. TJU and UMES shall review those calculations and shall notify UMB of any discrepancies within fifteen (15) days after receipt of that report. 

  
 5 

 5.2 After the parties approve the calculations in accordance with Section 5.1. UMB shall
disburse as follows: 
 5.2.1 First, to each party in an amount necessary to reimburse any outstanding Patent Expenses; 

5.2.2 Second, to UMB the Administrative Fee, if applicable; and 

5.2.3 Then, remaining Net Revenues shall be disbursed as follows: 

(a) If the Net Revenues are specifically allocable to the Joint Invention, remaining Net Revenues shall be disbursed
[REDACTED]; or 
 (b) If the Net Revenues are not specifically allocable to the Joint Invention, remaining Net Revenues shall
be disbursed [REDACTED]; or 
 provided, however, if the Tokai MLA is further amended such that there are a different total number of licensed
technologies, then the parties will negotiate reasonably and in good faith a different sharing of Net Revenues than that set forth in this Section 5.2.3. 

5.3 UMB shall pay to TJU and UMES its share of Net Revenues concurrently with the distributions it makes to its own Inventors, but in any case
no later than June 30 for the preceding calendar year. 
 5.4 Each party shall be responsible for distributing a portion of its
respective share of Net Revenues to its Inventor(s), as required. 
 5.5 During the term of this Agreement and for [**] years after its
expiration or termination, UMB shall keep (and shall require Tokai to keep) complete, true, and accurate records containing all the particulars that may be necessary to determine Net Revenues, the Administrative Fee, Patent Expenses, or other
amounts payable under this Agreement. The records shall be subject to inspection at any time during regular business hours upon reasonable notice by an independent auditor appointed by TJU or UMES for this purpose and reasonably acceptable to UMB.
The auditor shall report only the amount of Net Revenues, Administrative Fees, Patent Expenses, or other amounts payable under this Agreement. This audit shall be at TJU’s or UMES’ expense; provided, however, if the audit
shows an underpayment often percent (10%) or more, the audit expense shall be payable by UMB. 
 ARTICLE 6. INFRINGEMENT 

6.1 Management of Proceedings. 

6.1.1 If a party has knowledge of or reasonable grounds to suspect any infringement of the Patent Rights, it shall promptly
provide notice to the other parties. If required by the Tokai MLA, UMB shall be responsible to provide notice of infringement to Tokai. 

  
 6 

 6.1.2 Pursuant to the Tokai MLA, Tokai in its own name, at its own expense, and
on its own behalf may bring suit for any infringement, or defend a suit alleging invalidity or non-infringement of the Patent Rights. In that event, UMB shall use reasonable efforts to ensure that Tokai manages the proceedings related to the
infringement according to the terms of the Tokai MLA. If a suit is filed or defended by Tokai, each party may join in the suit at its own expense, but otherwise the parties shall take no action with respect to the infringement. 

6.1.3 If (a) Tokai fails to take actions regarding the infringement required by the Tokai MLA, or (c) Tokai provides
notice to UMB that Tokai has decided not to take any action, the parties shall by mutual agreement determine which party will be primarily responsible for attempting to terminate the infringement. If the parties are unable to agree in a timely
manner, UMB shall be primarily responsible. The designated party shall use reasonable efforts, in cooperation with the other party and to the extent permitted by the Tokai MLA, to terminate the infringement without litigation. 

6.1.4 If the infringement is not eliminated within [**] days after notice to the infringer, and if Tokai will not be
instituting suit or managing the proceedings (as set forth in Section 6.1.3), each party shall have the right after consulting with the other parties to: (a) commence suit on its own account; (b) join with the other parties and/or
Tokai in that suit; or (c) refuse to participate in that suit. 
 6.1.5 Each party agrees to cooperate in any
infringement proceeding instituted under this Agreement. An infringement proceeding (including any settlement) shall be controlled by the party bringing the suit; provided, however, that UMB shall control the suit if brought jointly,
unless UMB joins only as a nominal plaintiff. Each party shall request its Inventor(s) and other relevant personnel to cooperate with and to assist to the extent reasonably required in connection with any infringement proceeding. 

6.2 Expenses and Recoveries. 

6.2.1 If the parties join in any suit for infringement solely regarding the Joint Invention: (a) [REDACTED] (including
without limitation counsel fees, expert witness fees, and discovery costs); and (b) all recoveries received [REDACTED]. 

6.2.2 If the parties join in any suit for infringement which regards the Joint Invention in addition to any other
technology(ies) (including without limitation the UMB Technologies), the parties shall negotiate reasonably and in good faith a different sharing of expenses and recoveries. 

6.2.3 Any party bringing a suit on its own account shall be solely responsible for all litigation expenses incurred in
connection with that action, and shall be entitled to retain all recoveries as a result of that action. 
 ARTICLE 7. TERM AND TERMINATION

 7.1 Term. Unless sooner terminated in accordance with this Article 7, this Agreement will continue in full force and effect
until the later of: (a) the date of expiration of the last to 

  
 7 

 
expire of the claims of the Patent Rights; (b) ten (10) years after the Effective Date); or (c) the expiration or termination of the Tokai MLA if they extend beyond clause
(a) and (b) (the “Term”). 
 7.2 Unilateral Termination. Either party may terminate this Agreement by
giving ninety (90) days notice to the other party. 
 7.3 Termination Upon Default. If a party defaults in the performance of
any material obligation under this Agreement, and the default has not been remedied to the other parties’ reasonable satisfaction within sixty (60) days after the date of written notice of that default, the non-defaulting parties may by
written notice to the defaulting party terminate this Agreement effective immediately. 
 7.4 Effect of Termination. 

7.4.1 Termination or expiration of this Agreement does not relieve any party of any obligation which arises before expiration
or termination, including without limitation any obligation to distribute Net Revenues, to reimburse Patent Expenses, and to cooperate and share expenses for pursuit of infringement. Any provision of this Agreement which contemplates performance or
observance subsequent to any termination or expiration of this Agreement shall survive any termination or expiration of this Agreement and continue in full force and effect. 

7.4.2 Termination or expiration shall not affect the Tokai MLA. The applicable provisions of this Agreement shall continue to
be applied with respect to the Tokai MLA, notwithstanding the termination or expiration of this Agreement. 
 7.4.3 In
addition, upon any termination or expiration: 
 (a) Each party shall continue to own an undivided joint interest in the
Joint Invention and the related Patent Rights. 
 (b) Each party shall make available to the other party copies of all
relevant documents called for under the Agreement applicable to the Joint Invention, to the extent that copies have not been furnished previously. 

ARTICLE 8. DISCLAIMER OF WARRANTIES; LIMITATION OF LIABILITY 

8.1 DISCLAIMER OF WARRANTIES. THE JOINT INVENTION, PATENT RIGHTS, LICENSED PRODUCTS, AND UMB CONFIDENTIAL INFORMATION ARE “AS
IS.” EACH PARTY DISCLAIMS ALL EXPRESS OR IMPLIED REPRESENTATIONS OR WARRANTIES REGARDING THE JOINT INVENTION, PATENT RIGHTS, PATENT APPLICATIONS, LICENSED PRODUCTS, OR CONFIDENTIAL INFORMATION, INCLUDING WITHOUT LIMITATION: SCOPE, VALIDITY OR
ENFORCEABILITY; WHETHER A PATENT APPLICATION WILL BE APPROVED OR THAT A PATENT WILL ISSUE; RELIABILITY, COMPLETENESS, OR ACCURACY OF CONFIDENTIAL INFORMATION; INFRINGEMENT OR NON-INFRINGEMENT; THE PERFORMANCE OF LICENSED PRODUCTS, INCLUDING WITHOUT
LIMITATION AS TO THEIR SAFETY, EFFECTIVENESS. OR COMMERCIAL VIABILITY; AND THE WARRANTIES OF 

  
 8 

 
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COURSE OF DEALING, OR USAGE OF TRADE. 

8.2 Limitation of Liability. In no event will any party’s liability of any kind include any special, indirect, incidental,
consequential or punitive losses or damages, even if the party has been advised of the possibility of such damages. 
 8.3 No Joint
Liability. The liability of the parties under this Agreement shall be several, and not joint and several. The parties agree that nothing in this Agreement shall be construed as implying joint liability in any case and that each party will be
solely responsible for its own acts or omissions. If an action is brought by an outside party against two or more parties to this Agreement, the parties agree that no party to this Agreement will be liable for an amount greater than its proportional
contribution to any finding of negligence upon which such action is based. 
 ARTICLE 9. NOTICES 

9.1 Notices. Notices under this Agreement shall be in writing and shall be delivered personally as proven by a signed
receipt, sent by a reputable, national overnight delivery service, charges prepaid, or sent by certified mail return receipt requested. Notices shall be addressed to a party at the address specified below, or at those other place or places as shall
from time to time be specified in a notice similarly given. All notices shall be effective upon receipt. 
  

					
	If to UMB:	  	If to TJU:	  	If to UMES:
	 Assistant Vice President, OTT Office of Research and Development

University of Maryland, Baltimore
 620 West Lexington Street, 4th
Floor
 Baltimore, Maryland 21201-1508
	  	 Office of Technology Transfer and Business Development

Thomas Jefferson University
 1020 Locust Street, Suite M34

Philadelphia, PA 19107
 Attn: Executive Director
	  	 c/o University of Maryland Office of Technology Commercialization

0133 Cole Student Activities Bldg.
 College Park, MD
20742-1001
 Attn: Executive Director

			
	Copy to:	  	Copy to:	  	Copy to:
			
	 University Counsel
 University of Maryland,
Baltimore
 220 Arch Street, Room 03-111
 Baltimore, Maryland
21201-1531
	  	 Office of University Counsel
 Thomas Jefferson
University
 1020 Walnut Street
 Philadelphia, PA 19107
	  	 Office of Legal Affairs
 University of
Maryland
 2101 Main Administration Bldg.
 College Park, MD
20742

 9.2 Changes of Address. Each party shall reasonably promptly notify the other party of any change
specifying that changed address for the delivery of notices or invoices. 
 ARTICLE 10. ASSIGNMENT 

10.1 General. This Agreement shall be binding upon and inure to the benefit of the parties and their respective legal representatives,
successors, and pennitted assigns. Any reference in this Agreement to a party shall be construed to include that party’s successors and permitted assigns. Any purported assignment in violation of this Section shall be null and void. 

10.2 Permitted Assignment. Either party may assign this Agreement to a successor-in-interest, but may not otherwise assign or transfer
this Agreement without the prior written consent of the other parties, which shall not be unreasonably withheld or delayed. Each party 

  
 9 

 
may also assign this Agreement to its Inventor(s), in the event of an assignment to the Inventor(s) of the Joint Invention pursuant to Federal IP Policy. 

ARTICLE 11. MISCELLANEOUS 
 11.1
Governing Law. This Agreement is made and shall be construed in accordance with the laws of the State of Maryland without regard to the principles of conflicts of laws. 

11.2 Jurisdiction. Each party consents to the jurisdiction of the Circuit Court of Baltimore City or Anne Arundel County, Maryland for
any suit relating to this Agreement, and agrees to file any such suit in one of those courts. 
 11.3 No Limitation of State
Defenses. No provision of this Agreement shall constitute or be construed as a limitation, abrogation, or waiver of any defense or limitation of liability available to the State of Maryland or its units (including without limitation USM, UMB,
and UMES), officials, or employees under Maryland or Federal law, including without limitation the defense of sovereign immunity or any other governmental immunity. 

11.4 Waiver of Trial by Jury. THE PARTIES WAIVE THEIR RIGHTS TO TRIAL BY JURY IN ANY LITIGATION BETWEEN THEM RELATING TO THIS
AGREEMENT. 
 11.5 Entire Agreement. This Agreement embodies the entire understanding between the parties with respect to the subject
matter of this Agreement. There are no contracts, understandings, conditions, warranties or representations, oral or written, express or implied, with reference to the subject matter of this Agreement that are not merged in this Agreement. 

11.6 Relationship Between the Parties. UMB, TJU, and UMES are not (and nothing in this Agreement may be construed to constitute them
as) partners, joint venturers, agents, representatives, or employees of the other. No party has any responsibility or liability for the actions of the other party except as specifically provided in this Agreement. 

11.7 Further Assurances. The parties shall execute and deliver and cause to be executed and delivered further agreements, instruments
and documents and shall take further actions as may reasonably be required or appropriate to carry out the terms and conditions of this Agreement. 

11.8 Use of Names; Publicity. None of the parties shall use the name, seal, logo, trademark, or service mark of the other or any of its
personnel, or any adaptation thereof, in any advertising, promotional, or sales literature without prior written consent obtained from the other parties. Either party may publicize the fact that the parties have entered into this Agreement. However,
press releases or other public releases of information shall be coordinated between the parties prior to release. 
 11.9 No Implied
Rights. Nothing in the Agreement shall be construed to imply any license rights or other commitments with respect to any future research, or any intellectual property rights, or any technology, other than for the express terms set forth in the
Agreement relative to the Joint Invention and Patent Rights. 

  
 10 

 11.10 Counterparts. This Agreement may be executed in any number of counterparts, each of
which shall be an original, and all of which shall together constitute one agreement. 
 [SIGNATURES ON FOLLOWING PAGE] 

  
 11 

 SIGNATURE PAGE TO 

INTER-INSTITUTIONAL AGREEMENT 

The parties have caused this Agreement to be executed by their duly authorized representatives, to be effective as of the date of the last
signature below. 
  

									
	WITNESS:	 		 	UNIVERSITY OF MARYLAND, BALTIMORE	 	
					
		 		 	By:	 	/s/ Philip J. Robilotto	 	(SEAL)
		 		 		 	Philip J. Robilotto	 	
		 		 	Title:	 	AVP/OTT	 	
		 		 	Date:	 	3-October-2013	 	
				
	WITNESS:	 		 	THOMAS JEFFERSON UNIVERSITY	 	
					
		 		 	By:	 	/s/ Theodore F. Tarasdin	 	(SEAL)
	/s/ illegible 10/18/13	 		 		 		 	
		 		 	Name:	 	Theodore F. Tarasdin	 	
		 		 	Title:	 	VPR	 	
		 		 	Date:	 	10/18/13	 	
				
	WITNESS:	 		 	UNIVERSITY OF MARYLAND, EASTERN SHORE	 	
					
		 		 	By:	 	University of Maryland, College Park Office of Technology Commercialization	 	
	/s/ Felicia Metz	 		 		 		 	
		 		 	By:	 	/s/ Gayatri Varma	 	(SEAL)
		 		 	Name:	 	Gayatri Varma, Ph.D	 	
		 		 	Title:	 	Executive Director	 	
		 		 	Date:	 	September 24, 2013	 	

  
 12 

 SCHEDULE A 

PATENT RIGHTS 
 [**] 

  
 13 

 SCHEDULE B 

STANDARD CONFIDENTIALITY PROVISIONS 
 1.
General Restrictions on Use and Disclosure. 
 1.1 A party (“Provider”) may disclose Confidential
Information to the other party (“Recipient”). For a period of [**] years following the disclosure, Recipient shall hold the Confidential Information in confidence, and may disclose or use the Confidential Information only as
permitted by this Agreement. Recipient shall not use Provider’s Confidential Information for any other purpose without the prior written consent of Provider, UMB, TJU, and UMES each shall have the right to use the Confidential Information for
its own Non-Commercial Uses. Notwithstanding the foregoing, each party is permitted to disclose the Confidential Information to the extent reasonably necessary to market the Joint Invention and to fulfill its obligations under this Agreement,
provided that any disclosure is made subject to confidentiality restrictions consistent with those in this Agreement. 
 1.2
Recipient shall use the level of care to prevent the unauthorized use or disclosure of Provider’s Confidential Information that Recipient exercises in preventing the unauthorized use or disclosure of its own Confidential Information. Recipient
may disclose Provider’s Confidential Information only to its personnel who have a need to know or require access to the Confidential Information for the purposes permitted by this Agreement. Any Confidential Information that would identify
human research subjects or patients shall be maintained confidentially in accordance with applicable law. 
 1.3 UMB, TJU,
and UMES are educational institutions with practices for protection of Confidential Information which differ from industry standards and practices. Each party shall only be required to use reasonable efforts to protect the confidentiality of the
other party’s Confidential Information in a manner consistent with the practices used by that party to protect its own Confidential Information. 

2. Permitted Use and Disclosure. 

2.1 The confidentiality obligations created by this Agreement shall not apply if and to the extent that: (a) the
information is generally available to the public (other than through Recipient’s breach of this Agreement, any other agreement, or applicable law, or any unauthorized act by the Recipient); (b) the information was already in the possession
of Recipient at the time of the disclosure (other than pursuant to a confidential disclosure agreement or any unauthorized act by Recipient); (c) the information is or was developed by Recipient independent of and with no reliance upon
information of Provider or any other information furnished to Recipient by Provider under obligation of confidentiality; (d) the disclosure or use is reasonably necessary to fulfill or comply with requirements of governmental authorities having
jurisdiction, including without limitation the U.S. Securities and Exchange Commission, National Institutes of Health, Food and Drug Administration, and U.S. Patent and Trademark Office, and foreign equivalents of the foregoing; or
(e) disclosure is required by law. 

  
 14 

 2.2 In the event of disclosure pursuant to clauses (d) or (e) of
Section 2.1, Recipient shall use reasonable efforts to give Provider prior written notice of disclosure. Recipient, consistent with its counsel’s advice, shall take reasonable and lawful actions to obtain confidential treatment for
disclosed information of the Provider and to minimize the extent of the disclosure, or allow Provider the opportunity to take those actions. 

2.3 Nothing in this Agreement contained shall preclude a party from disclosing to Tokai those aspects of the Joint Invention
necessary to evaluate and/or practice the Patent Rights in a limited role as licensee. Any disclosure to Tokai of Confidential Information shall be contingent upon execution by Tokai of a non-disclosure agreement substantially on the terms set forth
in this Schedule B. In the event of a dispute as to the applicability of this Section 2, the burden of proof shall be upon Recipient to demonstrate permissibility of disclosure or use. 

3. Markings and Legends. Provider shall use reasonable efforts to mark all Confidential Information disclosed to Recipient as
“Confidential.” If the Confidential Information is not in written or tangible form and marked “Confidential” when disclosed, Provider shall use reasonable efforts to summarize the information in writing, marked as
“Confidential”, and to provide the summary to Recipient within [**] days after disclosure of the Confidential Information to Recipient. To the extent Recipient has actual knowledge that information is Confidential Information, failure to
meet the marking requirements shall not affect Recipient’s confidentiality obligations under this Agreement. 
 4. Public
Information Act. This Agreement and Confidential Information provided to UMB or UMES under this Agreement is a public record when in the possession of UMB or UMES. It may be subject to inspection pursuant to the Public Information Act
(§10-611 et seq., State Government Article, Annotated Code of Maryland) (the “Public Information Act”). If TJU asserts that any Confidential Information provided under this Agreement is a trade secret, confidential
financial information, confidential unpublished scientific information, or confidential commercial information, which is exempt from disclosure under the Public Information Act, then UMB and/or UMES shall assert in response to any request for
inspection of TJU’s Confidential Information that inspection should be denied pursuant to § 10-617(d) of the Public Information Act, unless UMB and/or UMES determines on the advice of its counsel that TJU’s position is not reasonable.

 5. Government and Sponsor Rights. Confidential Information may have been developed under a grant or contract or in collaboration
with the U.S. Government, state governments, research sponsors, or other entities. They may have rights in Confidential Information and may have the right to license or use Confidential Information, Patent Rights, and/or Licensed Products. Upon
written request, each party shall provide the other party with further information about any sponsor’s or collaborator’s rights, subject to confidentiality obligations. 

6. Export Control Laws. To the best of its knowledge, Discloser shall notify Recipient, prior to disclosing any Confidential
Information, whether the information being disclosed is subject to any restrictions or controls imposed by the Arms Export Control Act; the Export Administration Act of 1979; the International Traffic in Arms Regulations; the Export Administration
Regulations; or any other rules or regulations pertaining to restrictions on use or 

  
 15 

 
disclosure of goods, information, or technology, of any applicable governmental agency (collectively, the “Export Control Laws”). Recipient shall use reasonable efforts to
prevent Confidential Information and any direct product thereof from being used for any purpose prohibited by the Export Control Laws, and to cause uses of that Confidential Information to comply with the Export Control Laws. 

7. Return or Destruction of Confidential Information. Upon expiration or termination of this Agreement for any reason, Recipient shall
either return or destroy Discloser’s Confidential Information, together with all copies and other forms of reproduction, and shall provide written notice to Discloser of same. However, Recipient may retain one copy of Discloser’s
Confidential Information in the event of any question or dispute concerning Recipient’s obligations under this Agreement. If and to the extent any regulatory agency requests access to a party’s files after the return of such Confidential
Information to the Provider, the party responding to the request may either refer that agency to the Provider, or the Provider shall grant limited access again to such materials to allow compliance with the request. 

  
 16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]